

## References

- 2021 Alzheimer's disease facts and figures. (2021). *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 17(3), 327–406. <https://doi.org/10.1002/alz.12328>
- 2023 Alzheimer's disease facts and figures. (2023). *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 19(4), 1598–695. <https://doi.org/10.1002/alz.13016>
- Abelein, A., Chen, G., Kitoka, K., Aleksis, R., Oleskovs, F., Sarr, M., Landreh, M., Pahnke, J., Nordling, K., Kronqvist, N., Jaudzems, K., Rising, A., Johansson, J., & Biverstål, H. (2020). High-yield Production of Amyloid- $\beta$  Peptide Enabled by a Customized Spider Silk Domain. *Scientific Reports*, 10(1), 235. <https://doi.org/10.1038/s41598-019-57143-x>
- Ackaert, C., Smiejkowska, N., Xavier, C., Sterckx, Y. G. J., Denies, S., Stijlemans, B., Elkrim, Y., Devoogdt, N., Caveliers, V., Lahoutte, T., Muyltermans, S., Breckpot, K., & Keyaerts, M. (2021). Immunogenicity Risk Profile of Nanobodies. *Frontier in Immunology*, 12, 632687. <https://doi.org/10.3389/fimmu.2021.632687>
- Ahmed M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J. I., Van Nostrand, W. E., Smith, S. O. (2010). Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. *Nat Struct Mol Biol*. May;17(5):561-7. doi: 10.1038/nsmb.1799. Epub 2010 Apr 11. PMID: 20383142; PMCID: PMC2922021.
- Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 7(3), 270–79.

Referee List (DOI 10.36253/fup\_referee\_list)

FUP Best Practice in Scholarly Publishing (DOI 10.36253/fup\_best\_practice)

References. © Author(s), CC BY 4.0, DOI 10.36253/979-12-215-0993-9.references, in Liliana Napolitano, *A multidisciplinary approach for the early diagnosis of Alzheimer's disease and potential therapeutic applications*, pp. 129-172, 2026, published by Firenze University Press, ISBN 979-12-215-0993-9, DOI 10.36253/979-12-215-0993-9

- <https://doi.org/10.1016/j.jalz.2011.03.008>
- Alonso, A. D., Cohen, L. S., Corbo, C., Morozova, V., ElIdrissi, A., Phillips, G., & Kleiman, F. E. (2018). Hyperphosphorylation of Tau Associates with Changes in Its Function Beyond Microtubule Stability. *Frontiers in Cellular Neuroscience*, *12*, 338. <https://doi.org/10.3389/fncel.2018.00338>
- Alzforum. 2023. Remternetug [cited 26 Apr 2023]. <https://www.alzforum.org/therapeutics/remternetug>.
- Alzheimer Europe. Dementia in Europe Yearbook 2019: estimating the prevalence of dementia in Europe. (2020).
- Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., & Murtagh, F. R. (1995). An English translation of Alzheimer's 1907 paper, 'Über eine eigenartige Erkrankung der Hirnrinde'. *Clinical Anatomy (New York, N.Y.)*, *8*(6), 429–31. <https://doi.org/10.1002/ca.980080612>
- Alzheimer's Disease and Dementia. Aducanumab Discontinued as an Alzheimer's Treatment. (n.d.). *Alzheimer's Disease and Dementia*. Retrieved 4 December 2024, from <https://alz.org/alzheimers-dementia/treatments/aducanumab>
- Amador-Ortiz, C., Lin, W.-L., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff-Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007). TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. *Annals of Neurology*, *61*(5), 435–45. <https://doi.org/10.1002/ana.21154>
- Amm, I., Sommer, T., & Wolf, D. H. (2014). Protein quality control and elimination of protein waste: The role of the ubiquitin-proteasome system. *Biochimica Et Biophysica Acta*, *1843*(1), 182–96. <https://doi.org/10.1016/j.bbamcr.2013.06.031>
- An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., Levey, A. I., Lah, J., Seyfried, N. T., Legido-Quigley, C., O'Brien, R., & Thambisetty, M. (2018). Evidence for brain glucose dysregulation in Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *14*(3), 318–29. <https://doi.org/10.1016/j.jalz.2017.09.011>
- Andrews, S. J., Renton, A. E., Fulton-Howard, B., Podlesny-Drabiniok, A., Marcora, E., & Goate, A. M. (2023). The complex genetic architecture of Alzheimer's disease: Novel insights and future directions. *EBioMedicine*, *90*, 104511. <https://doi.org/10.1016/j.ebiom.2023.104511>
- Angelova, P. R., & Abramov, A. Y. (2018). Role of mitochondrial ROS in the brain: From physiology to neurodegeneration. *FEBS Letters*, *592*(5), 692–702. <https://doi.org/10.1002/1873-3468.12964>
- Antonell, A., Mansilla, A., Rami, L., Lladó, A., Iranzo, A., Olives, J., Balasa, M., Sánchez-Valle, R., & Molinuevo, J. L. (2014). Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*, *42*(3), 901–8. <https://doi.org/10.3233/JAD-140624>
- Aprile, F. A., Sormanni, P., Perni, M., Arosio, P., Linse, S., Knowles, T. P. J., Dobson, C. M., & Vendruscolo, M. (2017). Selective targeting of primary and secondary nucleation pathways in A $\beta$ 42 aggregation using a rational antibody

- scanning method. *Science Advances*, 3(6), e1700488. <https://doi.org/10.1126/sciadv.1700488>
- Aprile, F. A., Sormanni, P., Podpolny, M., Chhangur, S., Needham, L.-M., Ruggeri, F. S., Perni, M., Limbocker, R., Heller, G. T., Sneideris, T., Scheidt, T., Mannini, B., Habchi, J., Lee, S. F., Salinas, P. C., Knowles, T. P. J., Dobson, C. M., & Vendruscolo, M. (2020). Rational design of a conformation-specific antibody for the quantification of A $\beta$  oligomers. *Proceedings of the National Academy of Sciences of the United States of America*, 117(24), 13509–18. <https://doi.org/10.1073/pnas.1919464117>
- Arbel-Ornath, M., Hudry, E., Boivin, J. R., Hashimoto, T., Takeda, S., Kuchibhotla, K. V., Hou, S., Lattarulo, C. R., Belcher, A. M., Shakerdge, N., Trujillo, P. B., Muzikansky, A., Betensky, R. A., Hyman, B. T., & Bacskai, B. J. (2017). Soluble oligomeric amyloid- $\beta$  induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. *Molecular Neurodegeneration*, 12(1), 27. <https://doi.org/10.1186/s13024-017-0169-9>
- Argos, P. (1990). An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. *Journal of Molecular Biology*, 211(4), 943–58. [https://doi.org/10.1016/0022-2836\(90\)90085-Z](https://doi.org/10.1016/0022-2836(90)90085-Z)
- Ariga, T., Kobayashi, K., Hasegawa, A., Kiso, M., Ishida, H., & Miyatake, T. (2001). Characterization of high-affinity binding between gangliosides and amyloid beta- protein. *Archives of Biochemistry and Biophysics*, 388(2), 225–30. <https://doi.org/10.1006/abbi.2001.2304>
- Arispe, N., Diaz, J. C., & Simakova, O. (2007). Abeta ion channels. Prospects for treating Alzheimer's disease with Abeta channel blockers. *Biochimica Et Biophysica Acta*, 1768(8), 1952–65. <https://doi.org/10.1016/j.bbamem.2007.03.014>
- Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussi re, T., Hamann, S., Cameron, T. O., & Weinreb, P. H. (2018). Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid- $\beta$ . *Scientific Reports*, 8(1), 6412. <https://doi.org/10.1038/s41598-018-24501-0>
- Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Sch ll, M., Troakes, C., Hye, A., Gauthier, S., Vanmechelen, E., Zetterberg, H., Rosa-Neto, P., & Blennow, K. (2021). Plasma p-tau231: A new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathologica*, 141(5), 709–24. <https://doi.org/10.1007/s00401-021-02275-6>
- B ckman, L., Jones, S., Berger, A.-K., Laukka, E. J., & Small, B. J. (2005). Cognitive impairment in preclinical Alzheimer's disease: A meta-analysis. *Neuropsychology*, 19(4), 520–31. <https://doi.org/10.1037/0894-4105.19.4.520>
- Baghallab, I., Reyes-Ruiz, J. M., Abulnaja, K., Huwait, E., & Glabe, C. (2018). Epitomic Characterization of the Specificity of the Anti-Amyloid A $\beta$  Monoclonal Antibodies 6E10 and 4G8. *Journal of Alzheimer's Disease: JAD*, 66(3), 1235–44. <https://doi.org/10.3233/JAD-180582>

- Balchin, D., Hayer-Hartl, M., & Hartl, F. U. (2016). In vivo aspects of protein folding and quality control. *Science (New York, N.Y.)*, 353(6294), aac4354. <https://doi.org/10.1126/science.aac4354>
- Banchelli, M., Cascella, R., D'Andrea, C., Cabaj, L., Osticioli, I., Ciofini, D., Li, M. S., Skupień, K., de Angelis, M., Siano, S., Cecchi, C., Pini, R., La Penna, G., Chiti, F., & Matteini, P. (2020). Nanoscopic insights into the surface conformation of neurotoxic amyloid  $\beta$  oligomers. *RSC Advances*, 10(37), 21907–13. <https://doi.org/10.1039/d0ra03799k>
- Barenholz, Y. (2004). Sphingomyelin and cholesterol: From membrane biophysics and rafts to potential medical applications. *Sub-Cellular Biochemistry*, 37, 167–215. [https://doi.org/10.1007/978-1-4757-5806-1\\_5](https://doi.org/10.1007/978-1-4757-5806-1_5)
- Barrera, N. P., Zhou, M., & Robinson, C. V. (2013). The role of lipids in defining membrane protein interactions: Insights from mass spectrometry. *Trends in Cell Biology*, 23(1), 1–8. <https://doi.org/10.1016/j.tcb.2012.08.007>
- Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., Holtzman, D. M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P. S., Ghetti, B., Klunk, W. E., McDade, E., ... Dominantly Inherited Alzheimer Network. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *The New England Journal of Medicine*, 367(9), 795–804. <https://doi.org/10.1056/NEJMoa1202753>
- Batko, J., Antosz, K., Miśków, W., Pszczołowska, M., Walczak, K., & Leszek, J. (2024). Chaperones-A New Class of Potential Therapeutic Targets in Alzheimer's Disease. *International Journal of Molecular Sciences*, 25(6), 3401. <https://doi.org/10.3390/ijms25063401>
- Bélanger, K., Iqbal, U., Tanha, J., MacKenzie, R., Moreno, M., & Stanimirovic, D. (2019). Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases. *Antibodies (Basel, Switzerland)*, 8(2), 27. <https://doi.org/10.3390/antib8020027>
- Bellomo, G., Toja, A., Paolini Paoletti, F., Ma, Y., Farris, C. M., Gaetani, L., Salvadori, N., Chiasserini, D., Wojdała, A. L., Concha-Marambio, L., & Parnetti, L. (2024). Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. *Alzheimer's & Dementia*, 20(4), 2444–52. <https://doi.org/10.1002/alz.13658>
- Benedet, A. L., Brum, W. S., Hansson, O., Alzheimer's Disease Neuroimaging Initiative, Karikari, T. K., Zimmer, E. R., Zetterberg, H., Blennow, K., & Ashton, N. J. (2022). The accuracy and robustness of plasma biomarker models for amyloid PET positivity. *Alzheimer's Research & Therapy*, 14(1), 26. <https://doi.org/10.1186/s13195-021-00942-0>
- Benilova, I., Karran, E., & De Strooper, B. (2012). The toxic A $\beta$  oligomer and Alzheimer's disease: An emperor in need of clothes. *Nature Neuroscience*, 15(3), 349–57. <https://doi.org/10.1038/nn.3028>
- Bento, C. F., Renna, M., Ghislat, G., Puri, C., Ashkenazi, A., Vicinanza, M., Menzies, F. M., & Rubinsztein, D. C. (2016). Mammalian Autophagy: How

- Does It Work? *Annual Review of Biochemistry*, 85, 685–713. <https://doi.org/10.1146/annurev-biochem-060815-014556>
- Berridge, M. J. (1998). Neuronal calcium signaling. *Neuron*, 21(1), 13–26. [https://doi.org/10.1016/s0896-6273\(00\)80510-3](https://doi.org/10.1016/s0896-6273(00)80510-3)
- Berridge, M. J., Lipp, P., & Bootman, M. D. (2000). The versatility and universality of calcium signalling. *Nature Reviews. Molecular Cell Biology*, 1(1), 11–21. <https://doi.org/10.1038/35036035>
- Bhatia, S., Rawal, R., Sharma, P., Singh, T., Singh, M., & Singh, V. (2022). Mitochondrial Dysfunction in Alzheimer’s Disease: Opportunities for Drug Development. *Current Neuropharmacology*, 20(4), 675–92. <https://doi.org/10.2174/1570159X19666210517114016>
- Bigi, A., Cascella, R., Fani, G., Bernacchioni, C., Cencetti, F., Bruni, P., Chiti, F., Donati, C., & Cecchi, C. (2023a). Sphingosine 1-phosphate attenuates neuronal dysfunction induced by amyloid- $\beta$  oligomers through endocytic internalization of NMDA receptors. *The FEBS Journal*, 290(1), 112–33. <https://doi.org/10.1111/febs.16579>
- Bigi, A., Fani, G., Bessi, V., Napolitano, L., Bagnoli, S., Ingannato, A., Neri, L., Cascella, R., Matteini, P., Sorbi, S., Nacmias, B., Cecchi, C., & Chiti, F. (2024a). Putative novel CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: The PRAMA cohort. *Translational Neurodegeneration*, 13(1), 14. <https://doi.org/10.1186/s40035-024-00405-0>
- Bigi, A., Loffredo, G., Cascella, R., & Cecchi, C. (2020). Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies. *Current Alzheimer Research*, 17(8), 722–34. <https://doi.org/10.2174/1567205017666201109093848>
- Bigi, A., Lombardo, E., Cascella, R., & Cecchi, C. (2023b). The Toxicity of Protein Aggregates: New Insights into the Mechanisms. *International Journal of Molecular Sciences*, 24(9), 7974. <https://doi.org/10.3390/ijms24097974>
- Bigi, A., Napolitano, L., Vadukul, D. M., Chiti, F., Cecchi, C., Aprile, F. A., & Cascella, R. (2024b). A single-domain antibody detects and neutralises toxic A $\beta$ 42 oligomers in the Alzheimer’s disease CSF. *Alzheimer’s Research & Therapy*, 16(1), 13. <https://doi.org/10.1186/s13195-023-01361-z>
- Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. *Clinical Pharmacology and Therapeutics*, 69(3), 89–95. <https://doi.org/10.1067/mcp.2001.113989>
- Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988). Single-chain antigen-binding proteins. *Science (New York, N.Y.)*, 242(4877), 423–26. <https://doi.org/10.1126/science.3140379>
- Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B., & Teplow, D. B. (2003). Amyloid beta-protein (A $\beta$ ) assembly: A $\beta$ 40 and A $\beta$ 42 oligomerize through distinct pathways. *Proceedings of the National Academy of Sciences of the United States of America*, 100(1), 330–35.

- <https://doi.org/10.1073/pnas.222681699>
- Blennow, K., Wallin, A., Agren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995). Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? *Molecular and Chemical Neuropathology*, 26(3), 231–45. <https://doi.org/10.1007/BF02815140>
- Blessed, G., Tomlinson, B. E., & Roth, M. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. *The British Journal of Psychiatry: The Journal of Mental Science*, 114(512), 797–811. <https://doi.org/10.1192/bjp.114.512.797>
- Bode, D. C., Freeley M., Nield J., Palma M., Viles J.H. (2019). Amyloid- $\beta$  oligomers have a profound detergent-like effect on lipid membrane bilayers, imaged by atomic force and electron microscopy. *J Biol Chem*. 294(19):7566-72. doi: 10.1074/jbc.AC118.007195.
- Boess, F., Sakaoka, S., Abi-Saab, D., Scelsi, M., delmar, P., Hofmann, C., Klein, G., Baudler, M., Doody, R., & Kerchner, G. (2021). Graduation study design: Evaluation of once-weekly subcutaneous administration of gantenerumab on brain amyloid load. *Alzheimer's & Dementia*, 17. <https://doi.org/10.1002/alz.052060>
- Bondi, M. W., Edmonds, E. C., & Salmon, D. P. (2017). Alzheimer's Disease: Past, Present, and Future. *Journal of the International Neuropsychological Society: JINS*, 23(9–10), 818–31. <https://doi.org/10.1017/S135561771700100X>
- Bondi, M. W., Monsch, A. U., Galasko, D., Butters, N., Salmon, D. P., & Delis, D. C. (1994). Preclinical cognitive markers of dementia of the Alzheimer type. *Neuropsychology*, 8(3), 374–84. <https://doi.org/10.1037/0894-4105.8.3.374>
- Braak, H., & Braak, E. (1994). Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. *Neurobiology of Aging*, 15(3), 355–56; discussion 379-80. [https://doi.org/10.1016/0197-4580\(94\)90032-9](https://doi.org/10.1016/0197-4580(94)90032-9)
- Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry*, 72, 248–54. <https://doi.org/10.1006/abio.1976.9999>
- Brehme, M., Voisine, C., Rolland, T., Wachi, S., Soper, J. H., Zhu, Y., Orton, K., Vilella, A., Garza, D., Vidal, M., Ge, H., & Morimoto, R. I. (2014). A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. *Cell Reports*, 9(3), 1135–50. <https://doi.org/10.1016/j.celrep.2014.09.042>
- Brilhante-da-Silva, N., de Oliveira Sousa, R. M., Arruda, A., Dos Santos, E. L., Marinho, A. C. M., Stabeli, R. G., Fernandes, C. F. C., & Pereira, S. D. S. (2021). Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms. *Molecular Diagnosis & Therapy*, 25(4), 439–56. <https://doi.org/10.1007/s40291-021-00533-7>
- Brodsky, H., Heffernan, M., Kochan, N. A., Draper, B., Trollor, J. N., Reppermund, S., Slavin, M. J., & Sachdev, P. S. (2013). Mild cognitive

- impairment in a community sample: The Sydney Memory and Ageing Study. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 9(3), 310-17.e1. <https://doi.org/10.1016/j.jalz.2011.11.010>
- Brooks, W. H. (2024). Polyamine Dysregulation and Nucleolar Disruption in Alzheimer's Disease. *Journal of Alzheimer's Disease*, 98(3), 837. <https://doi.org/10.3233/JAD-231184>
- Buchhave, P., Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., & Hansson, O. (2012). Cerebrospinal fluid levels of  $\beta$ -amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Archives of General Psychiatry*, 69(1), 98-106. <https://doi.org/10.1001/archgenpsychiatry.2011.155>
- Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C. J., Muralidharan, K. K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., ... Sandrock, A. (2022). Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. *The Journal of Prevention of Alzheimer's Disease*, 9(2), 197-210. <https://doi.org/10.14283/jpad.2022.30>
- Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism, and Alzheimer disease. *Nature Reviews. Neuroscience*, 20(3), 148. <https://doi.org/10.1038/s41583-019-0132-6>
- Cadonic, C., Sabbir, M. G., & Albensi, B. C. (2016). Mechanisms of Mitochondrial Dysfunction in Alzheimer's Disease. *Molecular Neurobiology*, 53(9), 6078-90. <https://doi.org/10.1007/s12035-015-9515-5>
- Caillé, I., Allinquant, B., Dupont, E., Bouillot, C., Langer, A., Müller, U., & Prochiantz, A. (2004). Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. *Development (Cambridge, England)*, 131(9), 2173-81. <https://doi.org/10.1242/dev.01103>
- Camberg, J., Doyle, S., Johnston, D., Wickner, S. (2013). Molecular Chaperones. 10.1016/B978-0-12-374984-0.00221-7.
- Canevari, L., Clark, J. B., & Bates, T. E. (1999). Beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. *FEBS Letters*, 457(1), 131-34. [https://doi.org/10.1016/s0014-5793\(99\)01028-5](https://doi.org/10.1016/s0014-5793(99)01028-5)
- Capitini, C., Conti, S., Perni, M., Guidi, F., Cascella, R., De Poli, A., Penco, A., Relini, A., Cecchi, C., & Chiti, F. (2014). TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. *PloS One*, 9(1), e86720. <https://doi.org/10.1371/journal.pone.0086720>
- Cardoso, F. M., Ibañez, L. I., Van den Hoecke, S., De Baets, S., Smet, A., Roose, K., Schepens, B., Descamps, F. J., Fiers, W., Muyldermans, S., Depicker, A., & Saelens, X. (2014). Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge. *Journal of Virology*, 88(15), 8278-96. <https://doi.org/10.1128/JVI.03178-13>

- Carmona, S., Hardy, J., & Guerreiro, R. (2018). The genetic landscape of Alzheimer disease. *Handbook of Clinical Neurology*, 148, 395–408. <https://doi.org/10.1016/B978-0-444-64076-5.00026-0>
- Caroli, A., & Frisoni, G. B. (2010). The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. *Neurobiol Aging*, Aug;31(8):1263-74. doi: 10.1016/j.neurobiolaging.2010.04.024. Epub 2010 Jun 11. PMID: 20538373; PMCID: PMC3467365.
- Cascella, R., & Cecchi, C. (2021). Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis. *International Journal of Molecular Sciences*, 22(9), 4914. <https://doi.org/10.3390/ijms22094914>
- Cascella, R., Bigi, A., Riffert, D. G., Gagliani, M. C., Ermini, E., Moretti, M., Cortese, K., Cecchi, C., & Chiti, F. (2022). A quantitative biology approach correlates neuronal toxicity with the largest inclusions of TDP-43. *Science Advances*, 8(30), eabm6376. <https://doi.org/10.1126/sciadv.abm6376>
- Cascella, R., Chen, S. W., Bigi, A., Camino, J. D., Xu, C. K., Dobson, C. M., Chiti, F., Cremades, N., & Cecchi, C. (2021). The release of toxic oligomers from  $\alpha$ -synuclein fibrils induces dysfunction in neuronal cells. *Nature Communications*, 12(1), 1814. <https://doi.org/10.1038/s41467-021-21937-3>.
- Cascella, R., Conti, S., Mannini, B., Li, X., Buxbaum, J. N., Tiribilli, B., Chiti, F., & Cecchi, C. (2013a). Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. *Biochimica Et Biophysica Acta*, 1832(12), 2302–14. <https://doi.org/10.1016/j.bbadis.2013.09.011>
- Cascella, R., Conti, S., Tatini, F., Evangelisti, E., Scartabelli, T., Casamenti, F., Wilson, M. R., Chiti, F., & Cecchi, C. (2013b). Extracellular chaperones prevent A $\beta$ 42- induced toxicity in rat brains. *Biochimica Et Biophysica Acta*, 1832(8), 1217–26. <https://doi.org/10.1016/j.bbadis.2013.04.012>
- Cascella, R., Evangelisti, E., Bigi, A., Becatti, M., Fiorillo, C., Stefani, M., Chiti, F., & Cecchi, C. (2017). Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload. *Journal of Alzheimer's Disease: JAD*, 60(3), 923–38. <https://doi.org/10.3233/JAD-170340>
- Cecchi, C., Nichino, D., Zampagni, M., Bernacchioni, C., Evangelisti, E., Pensalfini, A., Liguri, G., Gliozzi, A., Stefani, M., & Relini, A. (2009). A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. *Biochimica Et Biophysica Acta*, 1788(10), 2204–16. <https://doi.org/10.1016/j.bbamem.2009.07.019>
- Chasseigneaux, S., & Allinquant, B. (2012). Functions of A $\beta$ , sAPP $\alpha$  and sAPP $\beta$ : Similarities and differences. *Journal of Neurochemistry*, 120 Suppl 1, 99–108. <https://doi.org/10.1111/j.1471-4159.2011.07584.x>
- Chatani, E., Yuzu, K., Ohhashi, Y., & Goto, Y. (2021). Current Understanding of the Structure, Stability and Dynamic Properties of Amyloid Fibrils. *International Journal of Molecular Sciences*, 22(9), 4349. <https://doi.org/10.3390/ijms22094349>
- Chatziefstathiou, A., Canaslan, S., Kanata, E., Vekrellis, K., Constantinides, V. C., Paraskevas, G. P., Kapaki, E., Schmitz, M., Zerr, I., Xanthopoulos, K.,

- Sklaviadis, T., & Dafou, D. (2024). SIMOA Diagnostics on Alzheimer's Disease and Frontotemporal
- Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018). Oxidative stress and the amyloid beta peptide in Alzheimer's disease. *Redox Biology*, *14*, 450–64. <https://doi.org/10.1016/j.redox.2017.10.014>
- Chen, T., O'Gorman, J., Castrillo-Viguera, C., Rajagovindan, R., Curiale, G. G., Tian, Y., Patel, D., von Rosenstiel, P., von Hehn, C., Salloway, S., Hock, C., Nitsch, R. M., Haeblerlein, S. B., Sandrock, A., & Singhal, P. (2024). Results from the long- term extension of PRIME: A randomized Phase 1b trial of aducanumab. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *20*(5), 3406–15. <https://doi.org/10.1002/alz.13755>
- Chen, X., Zaro, J. L., & Shen, W.-C. (2013). Fusion protein linkers: Property, design and functionality. *Advanced Drug Delivery Reviews*, *65*(10), 1357–69. <https://doi.org/10.1016/j.addr.2012.09.039>
- Chen, Y.R., & Glabe, C. G. (2006). Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: Stable trimer or tetramer formation by Abeta42. *The Journal of Biological Chemistry*, *281*(34), 24414–22. <https://doi.org/10.1074/jbc.M602363200>
- Cheng, B., Gong, H., Xiao, H., Petersen, R.B., Zheng, L., Huang, K. (2013). Inhibiting Toxic Aggregation of Amyloidogenic Proteins: A Therapeutic Strategy for Protein Misfolding Diseases. *Biochim. Biophys. Acta (BBA)*, *1830*, 4860–71.
- Chételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., Carrillo, M. C., Dubois, B., Fjell, A.M., Frisoni, G. B., Hansson, O., Herholz, K., Hutton, B. F., Jack, C. R., Lammertsma, A. A., ... Drzezga, A. (2020). Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. *The Lancet. Neurology*, *19*(11), 951–62. [https://doi.org/10.1016/S1474-4422\(20\)30314-8](https://doi.org/10.1016/S1474-4422(20)30314-8)
- Chiti, F., & Dobson, C. M. (2006). Protein misfolding, functional amyloid, and human disease. *Annual Review of Biochemistry*, *75*, 333–66. <https://doi.org/10.1146/annurev.biochem.75.101304.123901>
- Chiti, F., & Dobson, C. M. (2017). Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. *Annual Review of Biochemistry*, *86*, 27–68. <https://doi.org/10.1146/annurev-biochem-061516-045115>.
- Ciechanover, A., & Brundin, P. (2003). The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. *Neuron*, *40*(2), 427–46. [https://doi.org/10.1016/s0896-6273\(03\)00606-8](https://doi.org/10.1016/s0896-6273(03)00606-8)
- Cinquanta, L., Fontana, D. E., & Bizzaro, N. (2017). Chemiluminescent immunoassay technology: What does it change in autoantibody detection? *Auto-Immunity Highlights*, *8*(1), 9. <https://doi.org/10.1007/s13317-017-0097-2>
- Clapham, D. E. (2007). Calcium signaling. *Cell*, *131*(6), 1047–58.

- <https://doi.org/10.1016/j.cell.2007.11.028>
- Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018). The Amyloid- $\beta$  Oligomer Hypothesis: Beginning of the Third Decade. *Journal of Alzheimer's Disease: JAD*, *64*(s1), S567–S610. <https://doi.org/10.3233/JAD-179941>
- Cohen, S. I. A., Linse, S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013). Proliferation of amyloid- $\beta$ 42 aggregates occurs through a secondary nucleation mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, *110*(24), 9758–63. <https://doi.org/10.1073/pnas.1218402110>
- Colom-Cadena, M., Gelpi, E., Charif, S., Belbin, O., Blesa, R., Martí, M. J., Clarimón, J., & Lleó, A. (2013). Confluence of  $\alpha$ -synuclein, tau, and  $\beta$ -amyloid pathologies in dementia with Lewy bodies. *Journal of Neuropathology and Experimental Neurology*, *72*(12), 1203–12. <https://doi.org/10.1097/NEN.0000000000000018>
- Colvin, M. T., Silvers, R., Ni, Q. Z., Can, T. V., Sergeev, I., Rosay, M., Donovan, K. J., Michael, B., Wall, J., Linse, S., Griffin, R. G. (2016). Atomic Resolution Structure of Monomorphic A $\beta$ 42 Amyloid Fibrils. *J Am Chem Soc.* *138*(30):9663-74. doi: 10.1021/jacs.6b05129. Epub 2016 Jul 14. PMID: 27355699; PMCID: PMC5389415.
- Congdon, E. E., & Sigurdsson, E. M. (2018). Tau-targeting therapies for Alzheimer disease. *Nature Reviews. Neurology*, *14*(7), 399–415. <https://doi.org/10.1038/s41582-018-0013-z>
- Corey-Bloom, J. (2002). The ABC of Alzheimer's disease: Cognitive changes and their management in Alzheimer's disease and related dementias. *International Psychogeriatrics*, *14* Supp 1, 51–75. <https://doi.org/10.1017/s1041610203008664>
- Cummings, J., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2024). Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. *BioDrugs*, *38*(1), 5–22. <https://doi.org/10.1007/s40259-023-00633-2>
- Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002). Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. *The Journal of Biological Chemistry*, *277*(35), 32046–53. <https://doi.org/10.1074/jbc.M201750200>
- Danis, C., Dupré, E., Zejneli, O., Caillierez, R., Arrial, A., Bégard, S., Mortelecque, J., Eddarkaoui, S., Loyens, A., Cantrelle, F.-X., Hanouille, X., Rain, J.-C., Colin, M., Buée, L., & Landrieu, I. (2022). Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. *Molecular Therapy: The Journal of the American Society of Gene Therapy*, *30*(4), 1484–99. <https://doi.org/10.1016/j.ymthe.2022.01.009>
- David, M. A., Jones, D. R., Tayebi, M. Potential candidate camelid antibodies for the treatment of protein-misfolding diseases. (2014). *J Neuroimmunol.* *272*(1-2):76-85. doi: 10.1016/j.jneuroim.2014.05.001. Epub 2014 May 10. PMID: 24864011.
- de la Monte, S. M., Tong M. Brain metabolic dysfunction at the core of

- Alzheimer's disease. (2014). *Biochem Pharmacol.* 88(4):548-59. doi: 10.1016/j.bcp.2013.12.012.
- De Strooper, B. (2003). Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. *Neuron*, 38(1), 9–12. [https://doi.org/10.1016/s0896-6273\(03\)00205-8](https://doi.org/10.1016/s0896-6273(03)00205-8)
- De Strooper, B., & Karran, E. (2016). The Cellular Phase of Alzheimer's Disease. *Cell*, 164(4), 603–15. <https://doi.org/10.1016/j.cell.2015.12.056>
- De, S., Whiten, D. R., Ruggeri, F. S., Hughes, C., Rodrigues, M., Sideris, D. I., Taylor, C. G., Aprile, F. A., Muyltermans, S., Knowles, T. P. J., Vendruscolo, M., Bryant, C., Blennow, K., Skoog, I., Kern, S., Zetterberg, H., & Klenerman, D. (2019). Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. *Acta Neuropathologica Communications*, 7(1), 120. <https://doi.org/10.1186/s40478-019-0777-4>
- Demattos, R. B., Lu, J., Tang, Y., Racke, M. M., Delong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., Kinley, R. D., Jordan, W. H., & Hutton, M. L. (2012). A plaque-specific antibody clears existing  $\beta$ -amyloid plaques in Alzheimer's disease mice. *Neuron*, 76(5), 908–20. <https://doi.org/10.1016/j.neuron.2012.10.029>
- Demuro, A., Mina, E., Kaye, R., Milton, S. C., Parker, I., & Glabe, C. G. (2005). Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. *The Journal of Biological Chemistry*, 280(17), 17294–300. <https://doi.org/10.1074/jbc.M500997200>
- Deng, J., Habib, A., Obregon, D. F., Barger, S. W., Giunta, B., Wang, Y.-J., Hou, H., Sawmiller, D., & Tan, J. (2015). Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3 $\beta$  signaling pathway. *Journal of Neurochemistry*, 135(3), 630–37. <https://doi.org/10.1111/jnc.13351>
- Dickerson, B. C., Wolk, D. A.; Alzheimer's Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. *Neurology*. (2012). Jan 10;78(2):84-90. doi: 10.1212/WNL.0b013e31823efc6c. Epub 2011 Dec 21. PMID: 22189451; PMCID: PMC3466670.
- Dickey, C. A., Koren, J., Zhang, Y.-J., Xu, Y.-F., Jinwal, U. K., Birnbaum, M. J., Monks, B., Sun, M., Cheng, J. Q., Patterson, C., Bailey, R. M., Dunmore, J., Soresh, S., Leon, C., Morgan, D., & Petrucelli, L. (2008). Akt and CHIP coregulate tau degradation through coordinated interactions. *Proceedings of the National Academy of Sciences of the United States of America*, 105(9), 3622–27. <https://doi.org/10.1073/pnas.0709180105>
- Ding, Q., Markesbery, W. R., Chen, Q., Li, F., & Keller, J. N. (2005). Ribosome dysfunction is an early event in Alzheimer's disease. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 25(40), 9171–75. <https://doi.org/10.1523/JNEUROSCI.3040-05.2005>
- Drews, A., De, S., Flagmeier, P., Wirthensohn, D. C., Chen, W.-H., Whiten, D. R., Rodrigues, M., Vincke, C., Muyltermans, S., Paterson, R. W., Slattery, C. F., Fox, N. C., Schott, J. M., Zetterberg, H., Dobson, C. M., Gandhi, S.,

- &Klenerman, D. (2017). Inhibiting the Ca<sup>2+</sup> Influx Induced by Human CSF. *Cell Reports*, 21(11), 3310–16. <https://doi.org/10.1016/j.celrep.2017.11.057>
- Dufour-Rainfray, D., Beaufile, E., Vourc'h, P., Vierron, E., Mereghetti, L., Gendrot, C., Hommet, C., Andres, C. R., Guilloteau, D., & Mondon, K. (2013). Total protein level in cerebrospinal fluid is stable in elderly adults. *Journal of the American Geriatrics Society*, 61(10), 1819–21. <https://doi.org/10.1111/jgs.12489>
- Edelman, G. M. (1970). The structure and function of antibodies. *Scientific American*, 223(2), 34–42. <https://doi.org/10.1038/scientificamerican0870-34>
- Eisenberg, D., & Jucker, M. (2012). The amyloid state of proteins in human diseases. *Cell*, 148(6), 1188–1203. <https://doi.org/10.1016/j.cell.2012.02.022>
- Eli Lilly and Company. Lilly—News Release. (2023). Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease. <https://investor.lilly.com/news-releases/news-releases-details/lillys-donanemab-significantly-slowed-cognitive-and-functional>.
- Engelman, D. M. (2005). Membranes are more mosaic than fluid. *Nature*, 438(7068), 578–80. <https://doi.org/10.1038/nature04394>
- Englund, H., Sehlin, D., Johansson, A. S., Nilsson, L. N., Gellerfors, P., Paulie, S., Lannfelt, L., Pettersson, F. E. (2007). Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. *J Neurochem*.103(1):334-45. doi: 10.1111/j.1471-4159.2007.04759.x.Epub 2007 Jul 10. PMID: 17623042.
- Esteves, A., Arduino, D., Silva, D. F., Martins-Branco, D., Oliveira, C., & Cardoso, S. (2009). *MITOCHONDRIAL METABOLISM IN AGE-RELATED NEURODEGENERATIVE DISORDERS: ALZHEIMER'S AND PARKINSON'S REVISITED* (pp. 187–244).
- Evangelisti, E., Cascella, R., Becatti, M., Marrazza, G., Dobson, C. M., Chiti, F., Stefani, M., & Cecchi, C. (2016). Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. *Scientific Reports*, 6, 32721. <https://doi.org/10.1038/srep32721>
- Evangelisti, E., Wright, D., Zampagni, M., Cascella, R., Fiorillo, C., Bagnoli, S., Relini, A., Nichino, D., Scartabelli, T., Nacmias, B., Sorbi, S., Cecchi, C. (2013) Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer's disease. *Curr Alzheimer Res*. Feb; 10(2):143-53. doi: 10.2174/1567205011310020004. PMID: 22950913.
- Evangelisti, E., Zampagni, M., Cascella, R., Becatti, M., Fiorillo, C., Caselli, A., Bagnoli, S., Nacmias, B., Cecchi, C. (2014) Plasma membrane injury depends on bilayer lipid composition in Alzheimer's disease. *J Alzheimers Dis*.41(1):289-300. doi: 10.3233/JAD-131406. PMID: 24614900.
- Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S.-K., Soininen, H., Maetzler, W., Leyhe, T., Bürger, K., Taniguchi, M., Urakami, K., Lista, S., Dubois, B., Blennow, K., & Hampel, H. (2015). CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. *Alzheimer's &*

- Dementia: The Journal of the Alzheimer's Association*, 11(11), 1306–15. <https://doi.org/10.1016/j.jalz.2014.12.006>
- Fabiani, C., & Antollini, S. S. (2019). Alzheimer's Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts. *Frontiers in Cellular Neuroscience*, 13, 309. <https://doi.org/10.3389/fncel.2019.00309>
- Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009). Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. *EMBO Molecular Medicine*, 1(8–9), 371–80. <https://doi.org/10.1002/emmm.200900048>
- Fani, G., La Torre, C. E., Cascella, R., Cecchi, C., Vendruscolo, M., & Chiti, F. (2022). Misfolded protein oligomers induce an increase of intracellular Ca<sup>2+</sup> causing an escalation of reactive oxidative species. *Cellular and Molecular Life Sciences: CMLS*, 79(9), 500. <https://doi.org/10.1007/s00018-022-04513-w>
- Fani, G., Mannini, B., Vecchi, G., Cascella, R., Cecchi, C., Dobson, C. M., Vendruscolo, M., & Chiti, F. (2021). A $\beta$  Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors. *ACS Chemical Neuroscience*, 12(4), 766–81. <https://doi.org/10.1021/acchemneuro.0c00811>
- FDA Office of the Commissioner. FDA. (2023) [cited 31 May 2023]. FDA Grants Accelerated Approval for Alzheimer's Disease Treatment. <https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment>.
- Ferrer, I. (2002). Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. *Neuropathology and Applied Neurobiology*, 28(6), 441–51. <https://doi.org/10.1046/j.1365-2990.2002.t01-1-00410.x>
- Ferrer, I., Blanco, R., Carmona, M., Puig, B., Barrachina, M., Gómez, C., & Ambrosio, S. (2001). Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. *Journal of Neural Transmission (Vienna, Austria: 1996)*, 108(12), 1383–96. <https://doi.org/10.1007/s007020100015>
- Finder, V. H., Vodopivec, I., Nitsch, R. M., & Glockshuber, R. (2010). The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. *Journal of Molecular Biology*, 396(1), 9–18. <https://doi.org/10.1016/j.jmb.2009.12.016>
- Fitzpatrick, A. W. P., Debelouchina, G. T., Bayro, M. J., Clare, D. K., Caporini, M. A., Bajaj, V. S., Jaroniec, C. P., Wang, L., Ladizhansky, V., Müller, S. A., MacPhee, C. E., Waudby, C. A., Mott, H. R., De Simone, A., Knowles, T. P. J., Saibil, H. R., Vendruscolo, M., Orlova, E. V., Griffin, R. G., & Dobson, C. M. (2013). Atomic structure and hierarchical assembly of a cross- $\beta$  amyloid

- fibril. *Proceedings of the National Academy of Sciences of the United States of America*, 110(14), 5468–73. <https://doi.org/10.1073/pnas.1219476110>
- Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Lee, W., Mo, H., Lopez, L., Moreno, S., Acosta-Baena, N., Giraldo, M., Garcia, G., Reiman, R. A., Huentelman, M. J., Kosik, K. S., Tariot, P. N., Lopera, F., Reiman, E. M. (2012). Flortbetapir PET analysis of amyloid- $\beta$  deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. *Lancet Neurol*.11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6. PMID: 23137949; PMCID: PMC3515078.
- Fletcher, J. (2023). *Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease*.
- Förster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., Bartenstein, P., & Drzezga, A. (2012). Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. *Biological Psychiatry*, 71(9), 792–97. <https://doi.org/10.1016/j.biopsych.2011.04.023>
- Friede, R. L., & Samorajski, T. (1970). Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. *The Anatomical Record*, 167(4), 379–87. <https://doi.org/10.1002/ar.1091670402>
- Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. *Nature Reviews. Neurology*, 6(2), 67–77. <https://doi.org/10.1038/nrneurol.2009.215>
- Frost, D., Gorman, P. M., Yip, C. M., & Chakrabarty, A. (2003). Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. *European Journal of Biochemistry*, 270(4), 654–63. <https://doi.org/10.1046/j.1432-1033.2003.03415.x>
- Fukuchi, K., Accavitti-Loper, M. A., Kim, H.-D., Tahara, K., Cao, Y., Lewis, T. L., Caughey, R. C., Kim, H., & Lalonde, R. (2006a). Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model. *Biochemical and Biophysical Research Communications*, 344(1), 79–86. <https://doi.org/10.1016/j.bbrc.2006.03.145>
- Fukuchi, K., Tahara, K., Kim, H.-D., Maxwell, J. A., Lewis, T. L., Accavitti-Loper, M. A., Kim, H., Ponnazhagan, S., & Lalonde, R. (2006b). Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. *Neurobiology of Disease*, 23(3), 502–11. <https://doi.org/10.1016/j.nbd.2006.04.012>
- Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010). High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*, 24(8), 2716–26. <https://doi.org/10.1096/fj.09-150359>
- Fukunaga, S., Ueno, H., Yamaguchi, T., Yano, Y., Hoshino, M., & Matsuzaki, K. (2012). GM1 cluster mediates formation of toxic A $\beta$  fibrils by providing

- hydrophobic environments. *Biochemistry*, 51(41), 8125–31. <https://doi.org/10.1021/bi300839u>
- Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005). Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, 102(7), 2273–76. <https://doi.org/10.1073/pnas.0409336102>
- Giacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., Bessi, V., & Nacmias, B. (2022). Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. *Journal of Neurology*, 269(8), 4270–80. <https://doi.org/10.1007/s00415-022-11055-5>
- Gibbs, E., Silverman, J. M., Zhao, B., Peng, X., Wang, J., Wellington, C. L., Mackenzie, I. R., Plotkin, S. S., Kaplan, J. M., & Cashman, N. R. (2019). A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease. *Scientific Reports*, 9(1), 9870. <https://doi.org/10.1038/s41598-019-46306-5>
- Gill, S. C., & von Hippel, P. H. (1989). Calculation of protein extinction coefficients from amino acid sequence data. *Analytical Biochemistry*, 182(2), 319–26. [https://doi.org/10.1016/0003-2697\(89\)90602-7](https://doi.org/10.1016/0003-2697(89)90602-7)
- Ginsberg, S. D., Galvin, J. E., Chiu, T. S., Lee, V. M., Masliah, E., Trojanowski, J. Q. (1998). RNA sequestration to pathological lesions of neurodegenerative diseases. *Acta Neuropathol.* 1998 Nov;96(5):487-94. doi: 10.1007/s004010050923. PMID: 9829812.
- Gisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016). Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. *EBioMedicine*, 3, 135–40. <https://doi.org/10.1016/j.ebiom.2015.11.036>
- Glenner, G. G., & Wong, C. W. (1984). Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. *Biochemical and Biophysical Research Communications*, 122(3), 1131–35. [https://doi.org/10.1016/0006-291x\(84\)91209-9](https://doi.org/10.1016/0006-291x(84)91209-9)
- Goedert M, Masuda-Suzukake M, Falcon B. (2017) Like prions: the propagation of aggregated tau and  $\alpha$ -synuclein in neurodegeneration. *Brain*. 140(2):266-78. doi: 10.1093/brain/aww230. Epub 2016 Sep 21. PMID: 27658420.
- Golde, T. E., Eckman, C. B., & Younkin, S. G. (2000). Biochemical detection of A $\beta$  isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. *Biochimica Et Biophysica Acta*, 1502(1), 172–87. [https://doi.org/10.1016/s0925-4439\(00\)00043-0](https://doi.org/10.1016/s0925-4439(00)00043-0)
- Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003). Alzheimer's disease-affected brain: Presence of oligomeric A $\beta$  ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proceedings of the National Academy of Sciences*

- of the United States of America, 100(18), 10417–22. <https://doi.org/10.1073/pnas.1834302100>
- Gorantla, N. V., & Chinnathambi, S. (2018). Tau Protein Squired by Molecular Chaperones During Alzheimer's Disease. *Journal of Molecular Neuroscience: MN*, 66(3), 356–68. <https://doi.org/10.1007/s12031-018-1174-3>
- Greenfield NJ. (2006). Using circular dichroism spectra to estimate protein secondary structure. *Nat Protoc.* 1(6):2876-90. doi: 10.1038/nprot.2006.202. PMID: 17406547; PMCID: PMC2728378
- Greenough, M. A., Camakaris, J., & Bush, A. I. (2013). Metal dyshomeostasis and oxidative stress in Alzheimer's disease. *Neurochemistry International*, 62(5), 540–55. <https://doi.org/10.1016/j.neuint.2012.08.014>
- Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012). The genetic architecture of Alzheimer's disease: Beyond APP, PSENs and APOE. *Neurobiology of Aging*, 33(3), 437–56. <https://doi.org/10.1016/j.neurobiolaging.2010.03.025>
- Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020). Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. *Molecular Neurodegeneration*, 15(1), 40. <https://doi.org/10.1186/s13024-020-00391-7>
- Habiba, U., Descallar, J., Kreilau, F., Adhikari, U. K., Kumar, S., Morley, J. W., Bui, B. V., Koronyo-Hamaoui, M., & Tayebi, M. (2021). Detection of retinal and blood A $\beta$  oligomers with nanobodies. *Alzheimer's & Dementia (Amsterdam, Netherlands)*, 13(1), e12193. <https://doi.org/10.1002/dad2.12193>
- Halliwell, B., & Gutteridge, J. M. C. (2015). *Free Radicals in Biology and Medicine*. Oxford University Press.
- Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., & Hamers, R. (1993). Naturally occurring antibodies devoid of light chains. *Nature*, 363(6428), 446–48. <https://doi.org/10.1038/363446a0>
- Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021a). Developing the ATX(N) classification for use across the Alzheimer disease continuum. *Nature Reviews. Neurology*, 17(9), 580–89. <https://doi.org/10.1038/s41582-021-00520-w>
- Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A. (2021b). The Amyloid- $\beta$  Pathway in Alzheimer's Disease. *Molecular Psychiatry*, 26(10), 5481–503. <https://doi.org/10.1038/s41380-021-01249-0>
- Hansen, D. V., Hanson, J. E., and Sheng, M. (2018). Microglia in Alzheimer's disease. *J Cell Biol.* 217(2):459-472. doi: 10.1083/jcb.201709069. Epub 2017 Dec 1. PMID: 29196460; PMCID: PMC5800817.
- Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., Zetterberg, H., Blennow, K., & Swedish BioFINDER study. (2017). Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. *Neurology*, 88(10), 930–37. <https://doi.org/10.1212/WNL.0000000000003680>

- Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019). Advantages and disadvantages of the use of the CSF Amyloid  $\beta$  (A $\beta$ ) 42/40 ratio in the diagnosis of Alzheimer's Disease. *Alzheimer's Research & Therapy*, *11*(1), 34. <https://doi.org/10.1186/s13195-019-0485-0>
- Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends in Pharmacological Sciences*, *12*(10), 383–88. [https://doi.org/10.1016/0165-6147\(91\)90609-v](https://doi.org/10.1016/0165-6147(91)90609-v)
- Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science (New York, N.Y.)*, *297*(5580), 353–56. <https://doi.org/10.1126/science.1072994>
- Hashimoto, M., Rockenstein, E., Crews, L., & Masliah, E. (2003). Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. *Neuromolecular Medicine*, *4*(1–2), 21–36. <https://doi.org/10.1385/NMM:4:1-2:21>
- Hebda, J.A. & Miranker, A.D. (2009). The Interplay of Catalysis and Toxicity by Amyloid Intermediates on Lipid Bilayers: Insights from Type II Diabetes. *Annu. Rev. Biophys.* 2009, *38*, 125–52.
- Hefti, F., Goure, W. F., Jerecic, J., Iverson, K. S., Walicke, P. A., & Krafft, G. A. (2013). The case for soluble A $\beta$  oligomers as a drug target in Alzheimer's disease. *Trends in Pharmacological Sciences*, *34*(5), 261–66. <https://doi.org/10.1016/j.tips.2013.03.002>
- Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., ... Kummer, M. P. (2015). Neuroinflammation in Alzheimer's disease. *The Lancet. Neurology*, *14*(4), 388–405. [https://doi.org/10.1016/S1474-4422\(15\)70016-5](https://doi.org/10.1016/S1474-4422(15)70016-5)
- Hepp, D. H., Vergoossen, D. L. E., Huisman, E., Lemstra, A. W., Netherlands Brain Bank, Berendse, H. W., Rozemuller, A. J., Foncke, E. M. J., & van de Berg, W. D. J. (2016). Distribution and Load of Amyloid- $\beta$  Pathology in Parkinson Disease and Dementia with Lewy Bodies. *Journal of Neuropathology and Experimental Neurology*, *75*(10), 936–45. <https://doi.org/10.1093/jnen/nlw070>
- Hernández-Ortega, K., Garcia-Esparcia, P., Gil, L., Lucas, J. J., & Ferrer, I. (2016). Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. *Brain Pathology (Zurich, Switzerland)*, *26*(5), 593–605. <https://doi.org/10.1111/bpa.12335>
- Herring, W. L., Gould, I. G., Fillit, H., Lindgren, P., Forrestal, F., Thompson, R., & Pemberton-Ross, P. (2021). Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease. *Neurology and Therapy*, *10*(2), 919–40. <https://doi.org/10.1007/s40120-021-00273-0>
- Hershko, A., & Ciechanover, A. (1998). The ubiquitin system. *Annual Review of Biochemistry*, *67*, 425–79. <https://doi.org/10.1146/annurev.biochem.67.1.425>
- Herskovits, A. Z., Locascio, J. J., Peskind, E. R., Li, G., & Hyman, B. T. (2013). A Luminex assay detects amyloid  $\beta$  oligomers in Alzheimer's disease

- cerebrospinal fluid. *PloS One*, 8(7), e67898. <https://doi.org/10.1371/journal.pone.0067898>
- Heyman, A., Peterson, B., Fillenbaum, G., & Pieper, C. (1996). The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease. *Neurology*, 46(3), 656–60. <https://doi.org/10.1212/wnl.46.3.656>
- Hillen, H., Barghorn, S., Striebinger, A., Labkovsky, B., Müller, R., Nimmrich, V., Nolte, M. W., Perez-Cruz, C., van der Auwera, I., van Leuven, F., van Gaalen, M., Beshpalov, A. Y., Schoemaker, H., Sullivan, J. P., & Ebert, U. (2010). Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 30(31), 10369–79. <https://doi.org/10.1523/JNEUROSCI.5721-09.2010>
- Hipp, M. S., Park, S.-H., & Hartl, F. U. (2014). Proteostasis impairment in protein- misfolding and -aggregation diseases. *Trends in Cell Biology*, 24(9), 506–14. <https://doi.org/10.1016/j.tcb.2014.05.003>
- Hodges, J. R., Graham, N., & Patterson, K. (1995). Charting the progression in semantic dementia: Implications for the organisation of semantic memory. *Memory (Hove, England)*, 3(3–4), 463–95. <https://doi.org/10.1080/09658219508253161>
- Hof, P. R., Vogt, B. A., Bouras, C., & Morrison, J. H. (1997). Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: A review of lesion distribution and circuit disconnection in cortical visual pathways. *Vision Research*, 37(24), 3609–25. [https://doi.org/10.1016/S0042-6989\(96\)00240-4](https://doi.org/10.1016/S0042-6989(96)00240-4)
- Hölttä, M., Hansson, O., Andreasson, U., Hertz, J., Minthon, L., Nägga, K., Andreasen, N., Zetterberg, H., & Blennow, K. (2013). Evaluating amyloid- $\beta$  oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. *PloS One*, 8(6), e66381. <https://doi.org/10.1371/journal.pone.0066381>
- Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., Lemere, C. A., Selkoe, D. J., Stevens, B. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science*. 352(6286):712-716. doi: 10.1126/science.aad8373.
- Hong, S., Ostaszewski, B. L., Yang, T., O'Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014). Soluble A $\beta$  oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. *Neuron*, 82(2), 308–19. <https://doi.org/10.1016/j.neuron.2014.02.027>
- Huang, W.-J., Zhang, X., & Chen, W.-W. (2016). Role of oxidative stress in Alzheimer's disease. *Biomedical Reports*, 4(5), 519–22. <https://doi.org/10.3892/br.2016.630>
- Huang, Y.R., & Liu, R.-T. (2020). The Toxicity and Polymorphism of  $\beta$ -Amyloid Oligomers. *International Journal of Molecular Sciences*, 21(12), 4477. <https://doi.org/10.3390/ijms21124477>

- Hubin, E., van Nuland, N. a. J., Broersen, K., & Pauwels, K. (2014). Transient dynamics of A $\beta$  contribute to toxicity in Alzheimer's disease. *Cellular and Molecular Life Sciences: CMLS*, 71(18), 3507–21. <https://doi.org/10.1007/s00018-014-1634-z>
- Hultberg, A., Temperton, N. J., Rosseels, V., Koenders, M., Gonzalez-Pajuelo, M., Schepens, B., Ibañez, L. I., Vanlandschoot, P., Schillemans, J., Saunders, M., Weiss, R. A., Saelens, X., Melero, J. A., Verrips, C. T., Van Gucht, S., & de Haard, H. J. (2011). Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. *PLoS One*, 6(4), e17665. <https://doi.org/10.1371/journal.pone.0017665>
- Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Brucoleri, R. E., Haber, E., & Crea, R. (1988). Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proceedings of the National Academy of Sciences*, 85(16), 5879–83. <https://doi.org/10.1073/pnas.85.16.5879>
- Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984). Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. *Science (New York, N.Y.)*, 225(4667), 1168–70. <https://doi.org/10.1126/science.6474172>
- Iadecola C. (2017). The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. *Neuron*, 96(1):17-42. doi: 10.1016/j.neuron.2017.07.030. PMID: 28957666; PMCID: PMC5657612.
- Jack, C. R., & Holtzman, D. M. (2013). Biomarker modeling of Alzheimer's disease. *Neuron*, 80(6), 1347–58. <https://doi.org/10.1016/j.neuron.2013.12.003>
- Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., ... Contributors. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 14(4), 535–62. <https://doi.org/10.1016/j.jalz.2018.02.018>
- Jack, C. R., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., O'Brien, P. C., Edland, S. D., Smith, G. E., Boeve, B. F., Tangalos, E. G., Kokmen, E., & Petersen, R. C. (2002). Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. *Neurology*, 58(5), 750–57. <https://doi.org/10.1212/wnl.58.5.750>
- Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., & Trojanowski, J. Q. (2013b). Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. *The Lancet. Neurology*, 12(2), 207–16. [https://doi.org/10.1016/S1474-4422\(12\)70291-0](https://doi.org/10.1016/S1474-4422(12)70291-0)
- Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M.

- W., Petersen, R. C., & Trojanowski, J. Q. (2010a). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *The Lancet. Neurology*, *9*(1), 119–28. [https://doi.org/10.1016/S1474-4422\(09\)70299-6](https://doi.org/10.1016/S1474-4422(09)70299-6)
- Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., & Petersen, R. C. (2008). 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. *Brain: A Journal of Neurology*, *131*(Pt 3), 665–80. <https://doi.org/10.1093/brain/awm336>
- Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M., Petersen, R. C., & Alzheimer's Disease Neuroimaging Initiative. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. *Brain: A Journal of Neurology*, *132*(Pt 5), 1355–65. <https://doi.org/10.1093/brain/awp062>
- Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., Boeve, B. F., Trojanowski, J. Q., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., Knopman, D. S., & Alzheimer's Disease Neuroimaging Initiative. (2012). Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. *Archives of Neurology*, *69*(7), 856–67. <https://doi.org/10.1001/archneurol.2011.3405>
- Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Knopman, D. S., & Alzheimer's Disease Neuroimaging Initiative. (2010b). Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. *Brain: A Journal of Neurology*, *133*(11), 3336–48. <https://doi.org/10.1093/brain/awq277>
- Jackson, R. J., Hellen, C. U. T., & Pestova, T. V. (2010). The mechanism of eukaryotic translation initiation and principles of its regulation. *Nature Reviews. Molecular Cell Biology*, *11*(2), 113–27. <https://doi.org/10.1038/nrm2838>
- Jagust, W. J. (2010). Amyloid imaging: Coming to a PET scanner near you. *Annals of Neurology*, *68*(3), 277–78. <https://doi.org/10.1002/ana.22144>
- Jakob-Roetne, R., & Jacobsen, H. (2009). Alzheimer's disease: From pathology to therapeutic approaches. *Angewandte Chemie (International Ed. in English)*, *48*(17), 3030–59. <https://doi.org/10.1002/anie.200802808>
- Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., Blennow, K., Reiman, E. M., Stomrud, E., Dage, J. L., & Hansson, O. (2020). Plasma P-tau181 in Alzheimer's disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's

- dementia. *Nature Medicine*, 26(3), 379–86. <https://doi.org/10.1038/s41591-020-0755-1>
- Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., Blennow, K., & Hansson, O. (2016). Plasma  $\beta$ -amyloid in Alzheimer's disease and vascular disease. *Scientific Reports*, 6, 26801. <https://doi.org/10.1038/srep26801>
- Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Amyloid Biomarker Study Group, Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I. S., Arnold, S. E., Baldeiras, I., Barthel, H., van Berckel, B. N. M., Bibeau, K., Blennow, K., ... Zetterberg, H. (2015). Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. *JAMA*, 313(19), 1924–38. <https://doi.org/10.1001/jama.2015.4668>
- Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. *Biochemistry*, 32(18), 4693–97. <https://doi.org/10.1021/bi00069a001>
- Jekel, K., Damian, M., Wattmo, C., Hausner, L., Bullock, R., Connelly, P. J., Dubois, B., Eriksdotter, M., Ewers, M., Graessel, E., Kramberger, M. G., Law, E., Mecocci, P., Molinuevo, J. L., Nygård, L., Olde-Rikkert, M. G., Orgogozo, J.-M., Pasquier, F., Peres, K., ... Frölich, L. (2015). Mild cognitive impairment and deficits in instrumental activities of daily living: A systematic review. *Alzheimer's Research & Therapy*, 7(1), 17. <https://doi.org/10.1186/s13195-015-0099-0>
- Ji, S.R., Wu, Y., & Sui, S. (2002). Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. *The Journal of Biological Chemistry*, 277(8), 6273–79. <https://doi.org/10.1074/jbc.M104146200>
- Jinwal, U. K., Trotter, J. H., Abisambra, J. F., Koren, J., Lawson, L. Y., Vestal, G. D., O'Leary, J. C., Johnson, A. G., Jin, Y., Jones, J. R., Li, Q., Weeber, E. J., & Dickey, C. A. (2011). The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. *The Journal of Biological Chemistry*, 286(19), 16976-83. <https://doi.org/10.1074/jbc.M110.182493>
- Johnson, J. K., Head, E., Kim, R., Starr, A., & Cotman, C. W. (1999). Clinical and pathological evidence for a frontal variant of Alzheimer disease. *Archives of Neurology*, 56(10), 1233–39. <https://doi.org/10.1001/archneur.56.10.1233>
- Kagan, B. L., Azimov, R., & Azimova, R. (2004). Amyloid peptide channels. *The Journal of Membrane Biology*, 202(1), 1–10. <https://doi.org/10.1007/s00232-004-0709-4>
- Kakio, A., Nishimoto, S. I., Yanagisawa, K., Kozutsumi, Y., & Matsuzaki, K. (2001). Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta- protein, an endogenous seed for Alzheimer amyloid. *The Journal of Biological Chemistry*, 276(27), 24985–90. <https://doi.org/10.1074/jbc.M100252200>
- Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., & Matsuzaki, K.

- (2002). Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: Importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. *Biochemistry*, 41(23), 7385–90. <https://doi.org/10.1021/bi0255874>
- Kamat, P. K., Kalani, A., Rai, S., Swarnkar, S., Tota, S., Nath, C., & Tyagi, N. (2016). Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies. *Molecular Neurobiology*, 53(1), 648–61. <https://doi.org/10.1007/s12035-014-9053-6>
- Kaneko, M., Koike, H., Saito, R., Kitamura, Y., Okuma, Y., & Nomura, Y. (2010). Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 30(11), 3924–32. <https://doi.org/10.1523/JNEUROSCI.2422-09.2010>
- Kaneko, M., Saito, R., Okuma, Y., & Nomura, Y. (2012). Possible involvement of ubiquitin ligase HRD1 insolubilization in amyloid  $\beta$  generation. *Biological & Pharmaceutical Bulletin*, 35(2), 269–72. <https://doi.org/10.1248/bpb.35.269>
- Kapasi A., DeCarli C., Schneider J. A. (2017). Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol.* 134:171–86. doi: 10.1007/s00401-017-1717-7.
- Karch, C. M., Cruchaga, C., & Goate, A. M. (2014). Alzheimer's disease genetics: From the bench to the clinic. *Neuron*, 83(1), 11–26. <https://doi.org/10.1016/j.neuron.2014.05.041>
- Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., Schöll, M., Massarweh, G., Soucy, J.-P., Höglund, K., Brinkmalm, G., Mattsson, N., Palmqvist, S., Gauthier, S., Stomrud, E., ... Blennow, K. (2020). Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. *The Lancet. Neurology*, 19(5), 422–33. [https://doi.org/10.1016/S1474-4422\(20\)30071-5](https://doi.org/10.1016/S1474-4422(20)30071-5)
- Karran, E., & De Strooper, B. (2022). The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics. *Nature Reviews. Drug Discovery*, 21(4), 306–18. <https://doi.org/10.1038/s41573-022-00391-w>
- Kasturirangan, S., Li, L., Emadi, S., Boddapati, S., Schulz, P., & Sierks, M. R. (2012). Nanobody specific for oligomeric  $\beta$ -amyloid stabilizes nontoxic form. *Neurobiology of Aging*, 33(7), 1320–28. <https://doi.org/10.1016/j.neurobiolaging.2010.09.020>
- Kaushik, S., Cuervo A.M. Proteostasis and aging. *Nat Med.* 2015 Dec;21(12):1406-15. doi: 10.1038/nm.4001. PMID: 26646497.
- Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Neucula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P., & Glabe, C. G. (2007). Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Molecular Neurodegeneration*, 2, 18.

- <https://doi.org/10.1186/1750-1326-2-18>
- Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science (New York, N.Y.)*, *300*(5618), 486–89. <https://doi.org/10.1126/science.1079469>
- Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., & Glabe, C. G. (2004). Permeabilization of lipid bilayers is a common conformation- dependent activity of soluble amyloid oligomers in protein misfolding diseases. *The Journal of Biological Chemistry*, *279*(45), 46363–66. <https://doi.org/10.1074/jbc.C400260200>
- Keck, S., Nitsch, R., Grune, T., & Ullrich, O. (2003). Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. *Journal of Neurochemistry*, *85*(1), 115–22. <https://doi.org/10.1046/j.1471-4159.2003.01642.x>
- Khachaturian, Z. S. (1989). The role of calcium regulation in brain aging: Reexamination of a hypothesis. *Aging (Milan, Italy)*, *1*(1), 17–34. <https://doi.org/10.1007/BF03323872>
- Kim, K. S., Wen, GY., Bancher, C., Chen, CMJ, Sapienza, V., Hong, H., Wisniewski HM. (1990) Detection and quantification of amyloid  $\beta$ -peptide with two mono- clonal antibodies. *Neurosci Res Comm*, *7*:113–22.
- Kim, S., Sharma, C., Jung, U. J., & Kim, S. R. (2023). Pathophysiological Role of Microglial Activation Induced by Blood-Borne Proteins in Alzheimer’s Disease. *Biomedicines*, *11*(5), 1383. <https://doi.org/10.3390/biomedicines11051383>
- Kim, S.I., Yi, J.S., & Ko, Y.G. (2006). Amyloid beta oligomerization is induced by brain lipid rafts. *Journal of Cellular Biochemistry*, *99*(3), 878–89. <https://doi.org/10.1002/jcb.20978>
- Kim, Y. E., Hipp, M. S., Bracher, A., Hayer-Hartl, M., & Hartl, F. U. (2013). Molecular chaperone functions in protein folding and proteostasis. *Annual Review of Biochemistry*, *82*, 323–55. <https://doi.org/10.1146/annurev-biochem-060208-092442>
- Kinger, S., Jagtap, Y. A., Kumar, P., Choudhary, A., Prasad, A., Prajapati, V. K., Kumar, A., Mehta, G., & Mishra, A. (2024). Proteostasis in neurodegenerative diseases. *Advances in Clinical Chemistry*, *121*, 270–333. <https://doi.org/10.1016/bs.acc.2024.04.002>
- Kish, S. J. (1997). Brain energy metabolizing enzymes in Alzheimer’s disease: Alpha- ketoglutarate dehydrogenase complex and cytochrome oxidase. *Annals of the New York Academy of Sciences*, *826*, 218–28. <https://doi.org/10.1111/j.1749-6632.1997.tb48473.x>
- Kleiger, G., & Mayor, T. (2014). Perilous journey: A tour of the ubiquitin-proteasome system. *Trends in Cell Biology*, *24*(6), 352–59. <https://doi.org/10.1016/j.tcb.2013.12.003>
- Klement, M., Liu, C., Loo, B. L. W., Choo, A. B.-H., Ow, D. S.-W., & Lee, D.-Y. (2015). Effect of linker flexibility and length on the functionality of a cytotoxic engineered antibody fragment. *Journal of Biotechnology*, *199*, 90–

97. <https://doi.org/10.1016/j.jbiotec.2015.02.008>
- Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., Selkoe, D. J., Anwyl, R., Walsh, D. M., & Rowan, M. J. (2008). Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: Prevention by systemic passive immunization. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 28(16), 4231–37. <https://doi.org/10.1523/JNEUROSCI.5161-07.2008>
- Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021). Alzheimer disease. *Nature Reviews. Disease Primers*, 7(1), 33. <https://doi.org/10.1038/s41572-021-00269-y>
- Kollmer, M., Close, W., Funk, L., Rasmussen, J., Bsoul, A., Schierhorn, A., Schmidt, M., Sigurdson, C. J., Jucker, M., & Fändrich, M. (2019). Cryo-EM structure and polymorphism of A $\beta$  amyloid fibrils purified from Alzheimer's brain tissue. *Nature Communications*, 10(1), 4760. <https://doi.org/10.1038/s41467-019-12683-8>
- Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986). Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*, 83(11), 4044–48. <https://doi.org/10.1073/pnas.83.11.4044>
- Kravats, A.N., Wickner, S., Camberg, J.L. (2022). Molecular Chaperones. *Ref. Modul. Life Sci.*
- Kremer, J. J., Pallitto, M. M., Sklansky, D. J., & Murphy, R. M. (2000). Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. *Biochemistry*, 39(33), 10309–18. <https://doi.org/10.1021/bi0001980>
- Kulichikhin, K. Y., Fedotov, S. A., Rubel, M. S., Zalutskaya, N. M., Zobnina, A. E., Malikova, O. A., Neznanov, N. G., Chernoff, Y. O., & Rubel, A. A. (2021). Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins. *Prion*, 15(1), 56–69. <https://doi.org/10.1080/19336896.2021.1917289>
- Labbadia, J., & Morimoto, R. I. (2015). The biology of proteostasis in aging and disease. *Annual Review of Biochemistry*, 84, 435–64. <https://doi.org/10.1146/annurev-biochem-060614-033955>
- Ladiwala, A. R. A., Litt, J., Kane, R. S., Aucoin, D. S., Smith, S. O., Ranjan, S., Davis, J., Van Nostrand, W. E., & Tessier, P. M. (2012). Conformational differences between two amyloid  $\beta$  oligomers of similar size and dissimilar toxicity. *The Journal of Biological Chemistry*, 287(29), 24765–73. <https://doi.org/10.1074/jbc.M111.329763>
- Lafaye, P., Achour, I., England, P., Duyckaerts, C., & Rougeon, F. (2009). Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent A $\beta$ -induced neurotoxicity and inhibit fibril formation. *Molecular Immunology*, 46(4), 695–704.

- <https://doi.org/10.1016/j.molimm.2008.09.008>
- LaFerla, F. M., Green, K. N., & Oddo, S. (2007). Intracellular amyloid-beta in Alzheimer's disease. *Nature Reviews. Neuroscience*, 8(7), 499–509. <https://doi.org/10.1038/nrn2168>
- Lafleche, G., & Albert, M. S. (1995). Executive function deficits in mild Alzheimer's disease. *Neuropsychology*, 9(3), 313–20. <https://doi.org/10.1037/0894-4105.9.3.313>
- Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., & Klein, W. L. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. *Proceedings of the National Academy of Sciences of the United States of America*, 95(11), 6448–53. <https://doi.org/10.1073/pnas.95.11.6448>
- Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L. (2001). Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. *Journal of Neurochemistry*, 79(3), 595–605. <https://doi.org/10.1046/j.1471-4159.2001.00592.x>
- Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., Jagust, W. J., & Alzheimer's Disease Neuroimaging Initiative. (2012). Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Annals of Neurology*, 72(4), 578–86. <https://doi.org/10.1002/ana.23650>
- Lardinois, O., Kirby, P. J., Morgan, D. L., Sills, R. C., Tomer, K. B., & Deterding, L. J. (2014). Mass spectrometric analysis of rat cerebrospinal fluid proteins following exposure to the neurotoxicant carbonyl sulfide. *Rapid Communications in Mass Spectrometry: RCM*, 28(23), 2531–38. <https://doi.org/10.1002/rcm.7046>
- Le Bastard, N., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J. J., Engelborghs, S. (2013). Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. *J Alzheimers Dis*.33(1):117-31. doi: 10.3233/JAD-2012-121246. PMID: 22936010.
- Lee, A. G. (2003). Lipid-protein interactions in biological membranes: A structural perspective. *Biochimica Et Biophysica Acta*, 1612(1), 1–40. [https://doi.org/10.1016/s0005-2736\(03\)00056-7](https://doi.org/10.1016/s0005-2736(03)00056-7)
- Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., Uchiyama, Y., Westaway, D., Cuervo, A. M., & Nixon, R. A. (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. *Cell*, 141(7), 1146–58. <https://doi.org/10.1016/j.cell.2010.05.008>
- Lesne, J., Chang, H.J., De Visch, A. *et al.* Structural basis for chemically-induced homodimerization of a single domain antibody. (2019). *Sci Rep* 9, 1840. <https://doi.org/10.1038/s41598-019-38752-y>

- Leuzy, A., Mattsson-Carlgrén, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022). Blood-based biomarkers for Alzheimer's disease. *EMBO Molecular Medicine*, *14*(1), e14408. <https://doi.org/10.15252/emmm.202114408>
- Lewczuk P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., Fagan, A. M. (2017). Cerebrospinal Fluid A $\beta$ 42/40 Corresponds Better than A $\beta$ 42 to Amyloid PET in Alzheimer's Disease. *J Alzheimers Dis.* *55*(2):813-22. doi: 10.3233/JAD-160722. PMID: 27792012; PMCID: PMC5147502.
- Li, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K., Halabisky, B., Deng, C., Mahley, R. W., & Huang, Y. (2009). GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. *Cell Stem Cell*, *5*(6), 634–45. <https://doi.org/10.1016/j.stem.2009.10.015>
- Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. *Neuron*, *62*(6), 788–801. <https://doi.org/10.1016/j.neuron.2009.05.012>
- Li, T., Vandesquille, M., Koukoulis, F., Duffeant, C., Youssef, I., Lenormand, P., Ganneau, C., Maskos, U., Czech, C., Grueninger, F., Duyckaerts, C., Dhenain, M., Bay, S., Delatour, B., & Lafaye, P. (2016). Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, *243*, 1–10. <https://doi.org/10.1016/j.jconrel.2016.09.019>
- Li, X., An, W.-L., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J.-J. (2004). Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. *Neuroreport*, *15*(14), 2237–40. <https://doi.org/10.1097/00001756-200410050-00019>
- Lin, H., Bhatia, R., & Lal, R. (2001). Amyloid beta protein forms ion channels: Implications for Alzheimer's disease pathophysiology. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*, *15*(13), 2433–44. <https://doi.org/10.1096/fj.01-0377com>
- Lin, M.S., Chen, L.Y., Wang, S. S. S., Chang, Y., & Chen, W.Y. (2008). Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide. *Colloids and Surfaces. B, Biointerfaces*, *65*(2), 172–77. <https://doi.org/10.1016/j.colsurfb.2008.03.012>
- Liu, C.C., Liu, C.C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. *Nature Reviews. Neurology*, *9*(2), 106–18. <https://doi.org/10.1038/nrneuro.2012.263>
- Liu, P., Li, L., He, F., Meng, F., Liu, X., Su, Y., Su, X., Luo, B., & Peng, G. (2023). Identification of Candidate Biomarkers of Alzheimer's Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics. *International Journal of Molecular Sciences*, *24*(18), 14225. <https://doi.org/10.3390/ijms241814225>
- Lo, R. Y., Hubbard, A. E., Shaw, L. M., Trojanowski, J. Q., Petersen, R. C., Aisen, P. S., Weiner, M. W., Jagust, W. J., & Alzheimer's Disease Neuroimaging

- Initiative. (2011). Longitudinal change of biomarkers in cognitive decline. *Archives of Neurology*, 68(10), 1257–66. <https://doi.org/10.1001/archneurol.2011.123>
- Lopez Salon, M., Pasquini, L., Besio Moreno, M., Pasquini, J. M., & Soto, E. (2003). Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. *Experimental Neurology*, 180(2), 131–43. [https://doi.org/10.1016/s0014-4886\(02\)00060-2](https://doi.org/10.1016/s0014-4886(02)00060-2)
- Löppönen, M., Rähkä, I., Isoaho, R., Vahlberg, T., & Kivelä, S.-L. (2003). Diagnosing cognitive impairment and dementia in primary health care—A more active approach is needed. *Age and Ageing*, 32(6), 606–12. <https://doi.org/10.1093/ageing/afg097>
- Love S. & Miners J. S. Cerebrovascular disease in ageing and Alzheimer's disease. (2016). *Acta Neuropathol.* 2016;131:645–58. doi: 10.1007/s00401-015-1522-0
- Lu, R. C., Tan, M. S., Wang, H., Xie, A. M., Yu, J. T., & Tan, L. (2014). Heat shock protein 70 in Alzheimer's disease. *BioMed Research International*, 2014, 435203. <https://doi.org/10.1155/2014/435203>
- Lusardi, T. A., Phillips, J. I., Wiedrick, J. T., Harrington, C. A., Lind, B., Lapidus, J. A., Quinn, J. F., & Saugstad, J. A. (2017). MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease. *Journal of Alzheimer's Disease: JAD*, 55(3), 1223–33. <https://doi.org/10.3233/JAD-160835>
- Manoutcharian, K., Acero, G., Munguia, M. E., Becerril, B., Massieu, L., Govezensky, T., Ortiz, E., Marks, J. D., Cao, C., Ugen, K., & Gevorkian, G. (2004). Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. *Neurobiology of Disease*, 17(1), 114–21. <https://doi.org/10.1016/j.nbd.2004.06.005>
- Marín-Argany, M., Rivera-Hernández, G., Martí, J., & Villegas, S. (2011). An anti-A $\beta$  (amyloid  $\beta$ ) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing A $\beta$  oligomers from the amyloid pathway. *The Biochemical Journal*, 437(1), 25–34. <https://doi.org/10.1042/BJ20101712>
- Martinez-Lopez, N., Athonvarangkul, D., & Singh, R. (2015). Autophagy and aging. *Advances in Experimental Medicine and Biology*, 847, 73–87. [https://doi.org/10.1007/978-1-4939-2404-2\\_3](https://doi.org/10.1007/978-1-4939-2404-2_3)
- Mason, R. P., Shoemaker, W. J., Shajenko, L., Chambers, T. E., & Herbert, L. G. (1992). Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. *Neurobiology of Aging*, 13(3), 413–19. [https://doi.org/10.1016/0197-4580\(92\)90116-f](https://doi.org/10.1016/0197-4580(92)90116-f)
- Mastrogicola, F., Lindsay, J. G., Bettendorff, L., Rice, J., & Kish, S. J. (1996). Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. *Annals of Neurology*, 39(5), 592–98. <https://doi.org/10.1002/ana.410390508>

- Matsuzaki, K. (2007). Physicochemical interactions of amyloid beta-peptide with lipid bilayers. *Biochimica Et Biophysica Acta*, 1768(8), 1935–42. <https://doi.org/10.1016/j.bbamem.2007.02.009>
- Matsuzaki, K., Kato, K., & Yanagisawa, K. (2010). Abeta polymerization through interaction with membrane gangliosides. *Biochimica Et Biophysica Acta*, 1801(8), 868–77. <https://doi.org/10.1016/j.bbaliip.2010.01.008>
- Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. *Nature*, 430(7000), 631–39. <https://doi.org/10.1038/nature02621>
- Mattson, M. P., Cheng, B., Davis, D., Bryant, K., Lieberburg, I., & Rydel, R. E. (1992). Beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 12(2), 376–89. <https://doi.org/10.1523/JNEUROSCI.12-02-00376.1992>
- Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., Herukka, S.-K., van der Flier, W. M., Blankenstein, M. A., Ewers, M., Rich, K., Kaiser, E., Verbeek, M., Tsolaki, M., Mulugeta, E., Rosén, E., Aarsland, D., Visser, P. J., Schröder, J., ... Blennow, K. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA*, 302(4), 385–93. <https://doi.org/10.1001/jama.2009.1064>
- McKeith, I.G., Boeve, B.F., Dickson, D.W., Halliday, G., Taylor, J.P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., Bayston, A., Beach, T. G., Blanc, F., Bohnen, N., Bonanni, L., Bras, J., Brundin, P., Burn, D., et al. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology*. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. PMID: 28592453; PMCID: PMC5496518.
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr, Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., Phelps, C. H. (2011), The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21. PMID: 21514250; PMCID: PMC3312024.
- McKinnon, C., & Tabrizi, S. J. (2014). The ubiquitin-proteasome system in neurodegeneration. *Antioxidants & Redox Signaling*, 21(17), 2302-21. <https://doi.org/10.1089/ars.2013.5802>
- McLaurin, J., Franklin, T., Fraser, P. E., & Chakrabarty, A. (1998). Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. *The Journal of Biological Chemistry*, 273(8), 4506–15. <https://doi.org/10.1074/jbc.273.8.4506>
- Mendez, M. F. (2017). Early-Onset Alzheimer Disease. *Neurologic Clinics*, 35(2), 263–81. <https://doi.org/10.1016/j.ncl.2017.01.005>
- Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023).

- Microglia in Alzheimer's disease: Pathogenesis, mechanisms, and therapeutic potentials. *Frontier in Aging Neuroscience*, 15. <https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2023.1201982>
- Miao, W. (2008). Electrogenerated chemiluminescence and its biorelated applications. *Chemical Reviews*, 108(7), 2506–53. <https://doi.org/10.1021/cr068083a>
- Micsónai, A., Wien, F., Bulyáki, É., Kun, J., Moussong, É., Lee, Y.-H., Goto, Y., Réfrégiers, M., & Kardos, J. (2018). BeStSel: A web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. *Nucleic Acids Research*, 46(W1), W315–W322. <https://doi.org/10.1093/nar/gky497>
- Mielke, M. M., & Fowler, N. R. (2024). Alzheimer disease blood biomarkers: Considerations for population-level use. *Nature Reviews. Neurology*, 20(8), 495–504. <https://doi.org/10.1038/s41582-024-00989-1>
- Milstein, C. (1980). Monoclonal antibodies. *Scientific American*, 243(4), 66–74. <https://doi.org/10.1038/scientificamerican1080-66>
- Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., & Alzheimer's Disease Neuroimaging Initiative. (2009). Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. *Brain: A Journal of Neurology*, 132(Pt 5), 1310–23. <https://doi.org/10.1093/brain/awn320>
- Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods*, 65(1–2), 55–63. [https://doi.org/10.1016/0022-1759\(83\)90303-4](https://doi.org/10.1016/0022-1759(83)90303-4)
- Murakami, K. (2014). Conformation-specific antibodies to target amyloid  $\beta$  oligomers and their application to immunotherapy for Alzheimer's disease. *Bioscience, Biotechnology, and Biochemistry*, 78(8), 1293–1305. <https://doi.org/10.1080/09168451.2014.940275>
- Muyldermans, S. (2013). Nanobodies: Natural single-domain antibodies. *Annual Review of Biochemistry*, 82, 775–97. <https://doi.org/10.1146/annurev-biochem-063011-092449>
- Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S. X., Hurtig, H., Duda, J. E., Arnold, S. E., Siderowf, A., Grossman, M., Leverenz, J. B., Woltjer, R., Lopez, O. L., Hamilton, R., Tsuang, D. W., Galasko, D., Masliah, E., Kaye, J., Clark, C. M., Montine, T. J., ... Trojanowski, J. Q. (2007). Comorbidity of TDP-43 proteinopathy in Lewy body related diseases. *Acta Neuropathologica*, 114(3), 221–29. <https://doi.org/10.1007/s00401-007-0261-2>
- Nalivaeva, N. N., & Turner, A. J. (2013). The amyloid precursor protein: A biochemical enigma in brain development, function and disease. *FEBS Letters*, 587(13), 2046–54. <https://doi.org/10.1016/j.febslet.2013.05.010>
- Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., Boone, K., Miller, B. L.,

- Cummings, J., & Benson, D. F. (1998). Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. *Neurology*, *51*(6), 1546–54. <https://doi.org/10.1212/wnl.51.6.1546>
- Nebes, R. D. (1989). Semantic memory in Alzheimer's disease. *Psychological Bulletin*, *106*(3), 377–94. <https://doi.org/10.1037/0033-2909.106.3.377>
- Nicolson, G. L. (2014). The Fluid-Mosaic Model of Membrane Structure: Still relevant to understanding the structure, function and dynamics of biological membranes after more than 40 years. *Biochimica Et Biophysica Acta*, *1838*(6), 1451–66. <https://doi.org/10.1016/j.bbamem.2013.10.019>
- Nikolaev, A., McLaughlin, T., O'Leary, D. D. M., & Tessier-Lavigne, M. (2009). APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature*, *457*(7232), 981–89. <https://doi.org/10.1038/nature07767>
- Nisbet, R. M., Nigro, J., Breheny, K., Caine, J., Hattarki, M. K., & Nuttall, S. D. (2013). Central amyloid- $\beta$ -specific single chain variable fragment ameliorates A $\beta$  aggregation and neurotoxicity. *Protein Engineering, Design & Selection: PEDS*, *26*(10), 571–80. <https://doi.org/10.1093/protein/gzt025>
- Nonaka, T., Masuda-Suzukake, M., & Hasegawa, M. (2018). Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases. *Neuropathology: Official Journal of the Japanese Society of Neuropathology*, *38*(1), 64–71. <https://doi.org/10.1111/neup.12427>
- Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., Chiba, S., Atwood, C. S., Petersen, R. B., & Smith, M. A. (2001). Oxidative damage is the earliest event in Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, *60*(8), 759–67. <https://doi.org/10.1093/jnen/60.8.759>
- Nyhus, C., Pihl, M., Hyttel, P., & Hall, V. (2019). Evidence for nucleolar dysfunction in Alzheimer's disease. *Reviews in the Neurosciences*, *30*, 685–700. <https://doi.org/10.1515/revneuro-2018-0104>
- O'Connor, A., Karikari, T. K., Poole, T., Ashton, N. J., Lantero Rodriguez, J., Khatun, A., Swift, I., Heslegrave, A. J., Abel, E., Chung, E., Weston, P. S. J., Pavisic, I. M., Ryan, N. S., Barker, S., Rossor, M. N., Polke, J. M., Frost, C., Mead, S., Blennow, K., ... Fox, N. C. (2021). Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: A longitudinal cohort study. *Molecular Psychiatry*, *26*(10), 5967–76. <https://doi.org/10.1038/s41380-020-0838-x>
- Obregon, D., Hou, H., Deng, J., Giunta, B., Tian, J., Darlington, D., Shahaduzzaman, M., Zhu, Y., Mori, T., Mattson, M. P., & Tan, J. (2012). Soluble amyloid precursor protein- $\alpha$  modulates  $\beta$ -secretase activity and amyloid- $\beta$  generation. *Nature Communications*, *3*, 777. <https://doi.org/10.1038/ncomms1781>
- Olsson, B., Alberg, L., Cullen, N. C., Michael, E., Wahlgren, L., Kroksmark, A.-K., Rostasy, K., Blennow, K., Zetterberg, H., & Tulinus, M. (2019). NFL is a marker of treatment response in children with SMA treated with nusinersen. *Journal of Neurology*, *266*(9), 2129–36. <https://doi.org/10.1007/s00415-019-09389-8>

- Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., Wu, E., Dakin, K., Petzold, M., Blennow, K., & Zetterberg, H. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis. *The Lancet. Neurology*, *15*(7), 673–84. [https://doi.org/10.1016/S1474-4422\(16\)00070-3](https://doi.org/10.1016/S1474-4422(16)00070-3)
- Ossenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., Ohlsson, T., Jögi, J., Tsai, R., La Joie, R., Kramer, J., Boxer, A. L., Gorno-Tempini, M. L., Miller, B. L., Choi, J. Y., ... Hansson, O. (2018). Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*, *320*(11), 1151–62. <https://doi.org/10.1001/jama.2018.12917>
- Ostrowitzki, S., Bittner, T., Sink, K. M., Mackey, H., Rabe, C., Honig, L. S., Cassetta, E., Woodward, M., Boada, M., van Dyck, C. H., Grimmer, T., Selkoe, D. J., Schneider, A., Blondeau, K., Hu, N., Quartino, A., Clayton, D., Dolton, M., Dang, Y., ... Doody, R. S. (2022). Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. *JAMA Neurology*, *79*(11), 1113–21. <https://doi.org/10.1001/jamaneurol.2022.2909>
- Ostrowitzki, S., Deptula, D., Thurjfjell, L., Barkhof, F., Bohrmann, B., Brooks, D. J., Klunk, W. E., Ashford, E., Yoo, K., Xu, Z. X., Loetscher, H., Santarelli, L. (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. *Arch Neurol.* Feb;69(2):198-207. doi: 10.1001/archneurol.2011.1538. Epub 2011 Oct 10. PMID: 21987394.
- Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., Benzinger, T., Fagan, A. M., Patterson, B. W., & Bateman, R. J. (2017). Amyloid  $\beta$  concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *13*(8), 841–49. <https://doi.org/10.1016/j.jalz.2017.06.2266>
- Pain, C., Dumont, J., & Dumoulin, M. (2015). Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. *Biochimie*, *111*, 82–106. <https://doi.org/10.1016/j.biochi.2015.01.012>
- Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., Mattsson-Carlgrén, N., Strandberg, O., Smith, R., Villegas, A., Sepulveda-Falla, D., Chai, X., Proctor, N. K., Beach, T. G., Blennow, K., ... Hansson, O. (2020). Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*, *324*(8), 772–81. <https://doi.org/10.1001/jama.2020.12134>
- Pannee, J., Shaw, L. M., Korecka, M., Waligorska, T., Teunissen, C. E., Stoops, E., Vanderstichele, H. M. J., Mauro, K., Verberk, I. M. W., Keshavan, A.,

- Pesini, P., Sarasa, L., Pascual-Lucas, M., Fandos, N., Allué, J.-A., Portelius, E., Andreasson, U., Yoda, R., Nakamura, A., ... Zetterberg, H. (2021). The global Alzheimer's Association round robin study on plasma amyloid  $\beta$  methods. *Alzheimer's & Dementia (Amsterdam, Netherlands)*, 13(1), e12242. <https://doi.org/10.1002/dad2.12242>
- Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019). Amyloid- $\beta$  immunotherapy for alzheimer disease: Is it now a long shot? *Annals of Neurology*, 85(3), 303–315. <https://doi.org/10.1002/ana.25410>
- Paravastu, A. K., Leapman, R. D., Yau, W.-M., & Tycko, R. (2008). Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. *Proceedings of the National Academy of Sciences of the United States of America*, 105(47), 18349–54. <https://doi.org/10.1073/pnas.0806270105>
- Parker, W. D., Filley, C. M., & Parks, J. K. (1990). Cytochrome oxidase deficiency in Alzheimer's disease. *Neurology*, 40(8), 1302–3. <https://doi.org/10.1212/wnl.40.8.1302>
- Perchiacca, J. M., Ladiwala, A. R. A., Bhattacharya, M., & Tessier, P. M. (2012). Structure-based design of conformation- and sequence-specific antibodies against amyloid  $\beta$ . *Proceedings of the National Academy of Sciences of the United States of America*, 109(1), 84–89. <https://doi.org/10.1073/pnas.1111232108>
- Pereira, C., Santos, M. S., & Oliveira, C. (1998). Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. *Neuroreport*, 9(8), 1749–55. <https://doi.org/10.1097/00001756-199806010-00015>
- Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009). Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. *Nature*, 461(7266), 916–22. <https://doi.org/10.1038/nature08538>
- Perry, R. J., & Hodges, J. R. (1999). Attention and executive deficits in Alzheimer's disease. A critical review. *Brain: A Journal of Neurology*, 122 (Pt 3), 383–404. <https://doi.org/10.1093/brain/122.3.383>
- Peters, C., Espinoza, M. P., Gallegos, S., Opazo, C., & Aguayo, L. G. (2015). Alzheimer's A $\beta$  interacts with cellular prion protein inducing neuronal membrane damage and synaptotoxicity. *Neurobiology of Aging*, 36(3), 1369–77. <https://doi.org/10.1016/j.neurobiolaging.2014.11.019>
- Pickford, F., Masliah, E., Britschgi, M., Lucin, K., Narasimhan, R., Jaeger, P. A., Small, S., Spencer, B., Rockenstein, E., Levine, B., & Wyss-Coray, T. (2008). The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. *The Journal of Clinical Investigation*, 118(6), 2190–99. <https://doi.org/10.1172/JCI33585>
- Pietrzak, M., Rempala, G., Nelson, P. T., Zheng, J.-J., & Hetman, M. (2011). Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease. *PLoS One*, 6(7), e22585. <https://doi.org/10.1371/journal.pone.0022585>
- Pollard, H.B., Rojas, E., Arispe, N. (1993). A New Hypothesis for the Mechanism of Amyloid Toxicity, Based on the Calcium Channel Activity of Amyloid Protein (A P) in Phospholipid Bilayer Membranes. *Ann. N. Y. Acad. Sci.* 695,

165–168

- Popugaeva, E., Pchitskaya, E., & Bezprozvanny, I. (2018). Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease. *Antioxidants & Redox Signaling*, 29(12), 1176–88. <https://doi.org/10.1089/ars.2018.7506>
- Praticò, D. (2008). Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. *Trends in Pharmacological Sciences*, 29(12), 609–15. <https://doi.org/10.1016/j.tips.2008.09.001>
- Rabinovici, G. D. (2019). Late-onset Alzheimer Disease. *Continuum (Minneapolis, Minn.)*, 25(1), 14–33. <https://doi.org/10.1212/CON.0000000000000700>
- Rai, S. N., Singh, C., Singh, A., Singh, M. P., & Singh, B. K. (2020). Mitochondrial Dysfunction: A Potential Therapeutic Target to Treat Alzheimer's Disease. *Molecular Neurobiology*, 57(7), 3075–88. <https://doi.org/10.1007/s12035-020-01945-y>
- Rasmussen, M. K., Mestre, H., & Nedergaard, M. (2018). The glymphatic pathway in neurological disorders. *The Lancet. Neurology*, 17(11), 1016–24. [https://doi.org/10.1016/S1474-4422\(18\)30318-1](https://doi.org/10.1016/S1474-4422(18)30318-1)
- Reed, B. R., Mungas, D., Farias, S. T., Harvey, D., Beckett, L., Widaman, K., Hinton, L., & DeCarli, C. (2010). Measuring cognitive reserve based on the decomposition of episodic memory variance. *Brain: A Journal of Neurology*, 133(Pt 8), 2196–209. <https://doi.org/10.1093/brain/awq154>
- Reese, L.C., Tagliatalata, G. A. (2011). Role for calcineurin in Alzheimer's disease. *Curr. Neuropharmacol.* 9, 685–92.
- Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del- Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., Giraldo, M., Acosta-Baena, N., Sperling, R. A., Dickerson, B., Stern, C. E., Tirado, V., Munoz, C., Reiman, R. A., Huentelman, M. J., ... Lopera, F. (2012). Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. *The Lancet. Neurology*, 11(12), 1048–56. [https://doi.org/10.1016/S1474-4422\(12\)70228-4](https://doi.org/10.1016/S1474-4422(12)70228-4)
- Reiss, A. B., Arain, H. A., Stecker, M. M., Siegart, N. M., & Kasselmann, L. J. (2018). Amyloid toxicity in Alzheimer's disease. *Reviews in the Neurosciences*, 29(6), 613–27. <https://doi.org/10.1515/revneuro-2017-0063>
- Relkin, N., Marmarou, A., Klinge, P., Bergsneider, M., & Black, P. M. (2005). Diagnosing idiopathic normal-pressure hydrocephalus. *Neurosurgery*, 57(3 Suppl), S4–16; discussion ii–v. <https://doi.org/10.1227/01.neu.0000168185.29659.c5>
- Renner, J. A., Burns, J. M., Hou, C. E., McKeel, D. W., Storandt, M., & Morris, J. C. (2004). Progressive posterior cortical dysfunction: A clinicopathologic series. *Neurology*, 63(7), 1175–80. <https://doi.org/10.1212/01.wnl.0000140290.80962.bf>
- Revi, M. (2020). Alzheimer's Disease Therapeutic Approaches. *Advances in Experimental Medicine and Biology*, 1195, 105–16. [https://doi.org/10.1007/978-3-030-32633-3\\_15](https://doi.org/10.1007/978-3-030-32633-3_15)

- Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., Ferrell, E. P., Randall, J. D., Provuncher, G. K., Walt, D. R., & Duffy, D. C. (2010). Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. *Nature Biotechnology*, 28(6), 595–99. <https://doi.org/10.1038/nbt.1641>
- Robertson, D. S. (2010). The physical chemistry of brain and neural cell membranes: An overview. *Neurochemical Research*, 35(5), 681–87. <https://doi.org/10.1007/s11064-010-0121-7>
- Roychaudhuri, R., Yang, M., Hoshi, M. M., & Teplow, D. B. (2009). Amyloid beta-protein assembly and Alzheimer disease. *The Journal of Biological Chemistry*, 284(8), 4749–53. <https://doi.org/10.1074/jbc.R800036200>
- Rudajev, V., & Novotny, J. (2020). The Role of Lipid Environment in Ganglioside GM1-Induced Amyloid  $\beta$  Aggregation. *Membranes*, 10(9), 226. <https://doi.org/10.3390/membranes10090226>
- Sachdev, P., Kalaria, R., O'Brien, J., Skoog, I., Alladi, S., Black, S. E., Blacker, D., Blazer, D. G., Chen, C., Chui, H., Ganguli, M., Jellinger, K., Jeste, D. V., Pasquier, F., Paulsen, J., Prins, N., Rockwood, K., Roman, G., Scheltens, P., & International Society for Vascular Behavioral and Cognitive Disorders. (2014). Diagnostic criteria for vascular cognitive disorders: A VASCOG statement. *Alzheimer Disease and Associated Disorders*, 28(3), 206–18. <https://doi.org/10.1097/WAD.0000000000000034>
- Saido, T., & Leissring, M. A. (2012). Proteolytic degradation of amyloid  $\beta$ -protein. *Cold Spring Harbor Perspectives in Medicine*, 2(6), a006379. <https://doi.org/10.1101/cshperspect.a006379>
- Saito, R., Kaneko, M., Kitamura, Y., Takata, K., Kawada, K., Okuma, Y., & Nomura, Y. (2014). Effects of oxidative stress on the solubility of HRD1, a ubiquitin ligase implicated in Alzheimer's disease. *PloS One*, 9(5), e94576. <https://doi.org/10.1371/journal.pone.0094576>
- Saito, R., Kaneko, M., Okuma, Y., & Nomura, Y. (2010). Correlation between decrease in protein levels of ubiquitin ligase HRD1 and amyloid-beta production. *Journal of Pharmacological Sciences*, 113(3), 285–88. <https://doi.org/10.1254/jphs.10118sc>
- Sajdel-Sulkowska, E. M., & Marotta, C. A. (1984). Alzheimer's disease brain: Alterations in RNA levels and in a ribonuclease-inhibitor complex. *Science (New York, N.Y.)*, 225(4665), 947–49. <https://doi.org/10.1126/science.6206567>
- Sakono, M., & Zako, T. (2010). Amyloid oligomers: Formation and toxicity of Abeta oligomers. *The FEB Journal*, 277(6), 1348–58. <https://doi.org/10.1111/j.1742-4658.2010.07568.x>
- Samad, N., Ishaq, S., Bano, S., & Manzoor, N. (2017). Calcium Regulation in Alzheimer's Disease: Mechanistic Understanding. *Journal of the College of Physicians and Surgeons--Pakistan: JCPSP*, 27(9), 566–71.

- Santorio, M. M. & Bolen, D. W. Unfolding free energy changes determined by the linear extrapolation method. 1. Unfolding of phenylmethanesulfonyl .alpha.-chymotrypsin using different denaturants. *Biochemistry* **27**, 8063–8068 (1988)
- Santos, A. N., Torkler, S., Nowak, D., Schlittig, C., Goerdes, M., Lauber, T., Trischmann, L., Schaupp, M., Penz, M., Tiller, F.-W., & Böhm, G. (2007). Detection of amyloid-beta oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. *Journal of Alzheimer's Disease: JAD*, *11*(1), 117–25. <https://doi.org/10.3233/jad-2007-11114>
- Santos, R. X., Correia, S. C., Wang, X., Perry, G., Smith, M. A., Moreira, P. I., & Zhu, X. (2010). A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*, *20 Suppl 2*(Suppl 2), S401-12. <https://doi.org/10.3233/JAD-2010-100666>
- Savage, M. J., Kalinina, J., Wolfe, A., Tugusheva, K., Korn, R., Cash-Mason, T., Maxwell, J. W., Hatcher, N. G., Haugabook, S. J., Wu, G., Howell, B. J., Renger, J. J., Shughrue, P. J., & McCampbell, A. (2014). A sensitive  $\text{A}\beta$  oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, *34*(8), 2884-97. <https://doi.org/10.1523/JNEUROSCI.1675-13.2014>
- Scalia, F., Vitale, A. M., Santonocito, R., Conway de Macario, E., Macario, A. J. L., & Cappello, F. (2021). The Neurochaperonopathies: Anomalies of the Chaperone System with Pathogenic Effects in Neurodegenerative and Neuromuscular Disorders. *Applied Sciences*, *11*(3), Article 3. <https://doi.org/10.3390/app11030898>
- Schengrund, C.L. (2010). Lipid rafts: Keys to neurodegeneration. *Brain Research Bulletin*, *82*(1–2), 7–17. <https://doi.org/10.1016/j.brainresbull.2010.02.013>
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., ... Younkin, S. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nature Medicine*, *2*(8), 864–70. <https://doi.org/10.1038/nm0896-864>
- Schneider, J. A., Arvanitakis Z., Bang W., Bennett D. A. (2007). Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology*. 69:2197–204. doi: 10.1212/01.wnl.0000271090.28148.24.
- Schwab, C., Arai, T., Hasegawa, M., Yu, S., & McGeer, P. L. (2008). Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. *Journal of Neuropathology and Experimental Neurology*, *67*(12), 1159–65. <https://doi.org/10.1097/NEN.0b013e31818e8951>
- Sciacca, M. F. M., La Rosa, C., & Milardi, D. (2021). Amyloid-Mediated Mechanisms of Membrane Disruption. *Biophysica*, *1*(2), 137-56.

- <https://doi.org/10.3390/biophysical1020011>
- Selkoe, D. J. (1999). Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature*, 399(6738 Suppl), A23-31. <https://doi.org/10.1038/399a023>
- Selkoe, D. J. (2019). Alzheimer disease and aducanumab: Adjusting our approach. *Nature Reviews. Neurology*, 15(7), 365–66. <https://doi.org/10.1038/s41582-019-0205-1>
- Selles, M. C., Fortuna, J. T. S., Cercato, M. C., Santos, L. E., Domett, L., Bitencourt, A. L. B., Carraro, M. F., Souza, A. S., Janickova, H., Azevedo, C. V., Campos, H. C., de Souza, J. M., Alves-Leon, S., Prado, V. F., Prado, M. A. M., Epstein, A. L., Salvetti, A., Longo, B. M., Arancio, O., ... Ferreira, S. T. (2023). AAV-mediated neuronal expression of an scFv antibody selective for A $\beta$  oligomers protects synapses and rescues memory in Alzheimer models. *Molecular Therapy: The Journal of the American Society of Gene Therapy*, 31(2), 409–19. <https://doi.org/10.1016/j.ymthe.2022.11.002>
- Sengupta, U., Guerrero-Muñoz, M. J., Castillo-Carranza, D. L., Lasagna-Reeves, C. A., Gerson, J. E., Paulucci-Holthauzen, A. A., Krishnamurthy, S., Farhed, M., Jackson, G. R., & Kaye, R. (2015). Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. *Biological Psychiatry*, 78(10), 672–83. <https://doi.org/10.1016/j.biopsych.2014.12.019>
- Senjem, M. L., Gunter, J. L., Shiung, M. M., Petersen, R. C., & Jack, C. R. (2005). Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. *NeuroImage*, 26(2), 600–08. <https://doi.org/10.1016/j.neuroimage.2005.02.005>
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., ... Sandrock, A. (2016). The antibody aducanumab reduces A $\beta$  plaques in Alzheimer's disease. *Nature*, 537(7618), 50–56. <https://doi.org/10.1038/nature19323>
- Sewell, R. D. E. (Ed.). (2007). *Protein Misfolding in Neurodegenerative Diseases: Mechanisms and Therapeutic Strategies*. CRC Press. <https://doi.org/10.1201/9781420007145>
- Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M.-Y., Trojanowski, J. Q., & Alzheimer's Disease Neuroimaging Initiative. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. *Annals of Neurology*, 65(4), 403–13. <https://doi.org/10.1002/ana.21610>
- Sheu, K. F., Cooper, A. J., Koike, K., Koike, M., Lindsay, J. G., & Blass, J. P. (1994). Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease. *Annals of Neurology*, 35(3), 312–18. <https://doi.org/10.1002/ana.410350311>
- Sheu, K. F., Kim, Y. T., Blass, J. P., & Weksler, M. E. (1985). An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain.

- Annals of Neurology*, 17(5), 444–49. <https://doi.org/10.1002/ana.410170505>
- Shughrue, P. J., Acton, P. J., Breese, R. S., Zhao, W.-Q., Chen-Dodson, E., Hepler, R. W., Wolfe, A. L., Matthews, M., Heidecker, G. J., Joyce, J. G., Villarreal, S. A., & Kinney, G. G. (2010). Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. *Neurobiology of Aging*, 31(2), 189–202. <https://doi.org/10.1016/j.neurobiolaging.2008.04.003>
- Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023). Fluid biomarkers in Alzheimer’s disease. *Advances in Clinical Chemistry*, 112, 249–81. <https://doi.org/10.1016/bs.acc.2022.09.006>
- Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., Skovronsky, D. M., & TRAILBLAZER-ALZ 2 Investigators. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*, 330(6), 512–27. <https://doi.org/10.1001/jama.2023.13239>
- Sims, R., Hill, M., & Williams, J. (2020). The multiplex model of the genetics of Alzheimer’s disease. *Nature Neuroscience*, 23(3), 311–22. <https://doi.org/10.1038/s41593-020-0599-5>
- Singer, S. J., & Nicolson, G. L. (1972). The fluid mosaic model of the structure of cell membranes. *Science (New York, N.Y.)*, 175(4023), 720–31. <https://doi.org/10.1126/science.175.4023.720>
- Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2019). Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. *Molecules (Basel, Switzerland)*, 24(8), 1583. <https://doi.org/10.3390/molecules24081583>
- Somavarapu, A. K., & Kepp, K. P. (2015). The Dependence of Amyloid- $\beta$  Dynamics on Protein Force Fields and Water Models. *Chemphyschem: A European Journal of Chemical Physics and Physical Chemistry*, 16(15), 3278–89. <https://doi.org/10.1002/cphc.201500415>
- Song, S., Kim, S.-Y., Hong, Y.-M., Jo, D.-G., Lee, J.-Y., Shim, S. M., Chung, C.-W., Seo, S. J., Yoo, Y. J., Koh, J.-Y., Lee, M. C., Yates, A. J., Ichijo, H., & Jung, Y.-K. (2003). Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. *Molecular Cell*, 12(3), 553–63. <https://doi.org/10.1016/j.molcel.2003.08.005>
- Sorbi, S., Bird, E. D., & Blass, J. P. (1983). Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. *Annals of Neurology*, 13(1), 72–78. <https://doi.org/10.1002/ana.410130116>
- Sorbi, S., Nacmias, B., Forleo, P., Latorraca, S., Gobbini, I., Bracco, L., Piacentini, S., & Amaducci, L. (1994). ApoE allele frequencies in Italian sporadic and familial Alzheimer’s disease. *Neuroscience Letters*, 177(1–2), 100–2. [https://doi.org/10.1016/0304-3940\(94\)90054-x](https://doi.org/10.1016/0304-3940(94)90054-x)
- Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2015). Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. *Proceedings of the National Academy of Sciences of the United States of America*, 112(32), 9902–07. <https://doi.org/10.1073/pnas.1422401112>

- Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2018). Third generation antibody discovery methods: In silico rational design. *Chemical Society Reviews*, 47(24), 9137–57. <https://doi.org/10.1039/c8cs00523k>
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., ... Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 7(3), 280–92. <https://doi.org/10.1016/j.jalz.2011.03.003>
- Stewart, M. D., Ritterhoff, T., Klevit, R. E., & Brzovic, P. S. (2016). E2 enzymes: More than just middle men. *Cell Research*, 26(4), 423. <https://doi.org/10.1038/cr.2016.35>
- Strimbu, K., & Tavel, J. A. (2010). What are biomarkers? *Current Opinion in HIV and AIDS*, 5(6), 463–66. <https://doi.org/10.1097/COH.0b013e32833ed177>
- Sunde, M., & Blake, C. (1997). The structure of amyloid fibrils by electron microscopy and X-ray diffraction. *Advances in Protein Chemistry*, 50, 123–59. [https://doi.org/10.1016/s0065-3233\(08\)60320-4](https://doi.org/10.1016/s0065-3233(08)60320-4)
- Sutphen, C. L., Jasielc, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E. E. J., Vanderstichele, H. M. J., Brix, B., Darby, H. D., Vandijck, M. L. J., Ladenson, J. H., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015). Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. *JAMA Neurology*, 72(9), 1029–42. <https://doi.org/10.1001/jamaneurol.2015.1285>
- Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D. A., Berry, S., Gordon, R., Kramer, L. D., & Cummings, J. L. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A $\beta$  protofibril antibody. *Alzheimer's Research & Therapy*, 13(1), 80. <https://doi.org/10.1186/s13195-021-00813-8>
- Swerdlow, R. H. (2018). Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. *Journal of Alzheimer's Disease: JAD*, 62(3), 1403–16. <https://doi.org/10.3233/JAD-170585>
- Taipale, M., Jarosz, D. F., & Lindquist, S. (2010). HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. *Nature Reviews. Molecular Cell Biology*, 11(7), 515–28. <https://doi.org/10.1038/nrm2918>
- Tcw, J., & Goate, A. M. (2017). Genetics of  $\beta$ -Amyloid Precursor Protein in Alzheimer's Disease. *Cold Spring Harbor Perspectives in Medicine*, 7(6), a024539. <https://doi.org/10.1101/cshperspect.a024539>
- Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetsee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K.,

- Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., ... Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet. Neurology*, *17*(2), 162–73. [https://doi.org/10.1016/S1474-4422\(17\)30470-2](https://doi.org/10.1016/S1474-4422(17)30470-2)
- Tokunaga, Y., & Takeuchi, K. (2020). Role of NMR in High Ordered Structure Characterization of Monoclonal Antibodies. *International Journal of Molecular Sciences*, *22*(1), 46. <https://doi.org/10.3390/ijms22010046>
- Toledo J. B., Arnold S. E., Raible K., Brettschneider J., Xie S. X., Grossman M., Monsell S. E., Kukull W. A., Trojanowski J. Q. (2013). Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain*. 136:2697–706. doi: 10.1093/brain/awt188.
- Tu, S., Okamoto, S., Lipton, S. A., & Xu, H. (2014). Oligomeric A $\beta$ -induced synaptic dysfunction in Alzheimer's disease. *Molecular Neurodegeneration*, *9*, 48. <https://doi.org/10.1186/1750-1326-9-48>
- Twohig, D., & Nielsen, H. M. (2019).  $\alpha$ -synuclein in the pathophysiology of Alzheimer's disease. *Molecular Neurodegeneration*, *14*(1), 23. <https://doi.org/10.1186/s13024-019-0320-x>
- Vadukul, D. M., Papp, M., Thrush, R. J., Wang, J., Jin, Y., Arosio, P., & Aprile, F. A. (2023).  $\alpha$ -Synuclein Aggregation Is Triggered by Oligomeric Amyloid- $\beta$  42 via Heterogeneous Primary Nucleation. *Journal of the American Chemical Society*, *145*(33), 18276–285. <https://doi.org/10.1021/jacs.3c03212>
- Valdor, R., Mocholi, E., Botbol, Y., Guerrero-Ros, I., Chandra, D., Koga, H., Gravekamp, C., Cuervo, A. M., & Macian, F. (2014). Chaperone-mediated autophagy regulates T cell responses through targeted degradation of negative regulators of T cell activation. *Nature Immunology*, *15*(11), 1046-54. <https://doi.org/10.1038/ni.3003>
- van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in Early Alzheimer's Disease. *The New England Journal of Medicine*, *388*(1), 9–21. <https://doi.org/10.1056/NEJMoa2212948>
- Veerabhadrapa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2020). Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand? *Critical Reviews in Clinical Laboratory Sciences*, *57*(2), 99–113. <https://doi.org/10.1080/10408363.2019.1678011>
- Vemuri, P., Weigand, S. D., Przybelski, S. A., Knopman, D. S., Smith, G. E., Trojanowski, J. Q., Shaw, L. M., Decarli, C. S., Carmichael, O., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., & Alzheimer's Disease Neuroimaging Initiative. (2011). Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. *Brain: A Journal of Neurology*, *134*(Pt 5), 1479–92. <https://doi.org/10.1093/brain/awr049>

- Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., Jack, C. R., & Alzheimer's Disease Neuroimaging Initiative. (2009). MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. *Neurology*, *73*(4), 294–301. <https://doi.org/10.1212/WNL.0b013e3181af79fb>
- Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P.-J., Maruff, P., Skoog, I., Verhey, F. R. J., Freund-Levi, Y., Tsolaki, M., Wallin, Å. K., Olde Rikkert, M., Soininen, H., Spuru, L., Zetterberg, H., Blennow, K., ... ICTUS/DSA study groups. (2019). Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *15*(7), 888–98. <https://doi.org/10.1016/j.jalz.2019.04.001>
- Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeki, C., Macaulay, S. L., Martins, R., Maruff, P., Ames, D., Rowe, C. C., Masters, C. L., & Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. (2013). Amyloid  $\beta$  deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. *The Lancet. Neurology*, *12*(4), 357–67. [https://doi.org/10.1016/S1474-4422\(13\)70044-9](https://doi.org/10.1016/S1474-4422(13)70044-9)
- Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeki, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C. A., Klunk, W. E., Ames, D., Masters, C. L., & Rowe, C. C. (2011). Longitudinal assessment of A $\beta$  and cognition in aging and Alzheimer disease. *Annals of Neurology*, *69*(1), 181–92. <https://doi.org/10.1002/ana.22248>
- Vivekanandan, S., Brender, J. R., Lee, S. Y., & Ramamoorthy, A. (2011). A partially folded structure of amyloid-beta(1-40) in an aqueous environment. *Biochemical and Biophysical Research Communications*, *411*(2), 312–16. <https://doi.org/10.1016/j.bbrc.2011.06.133>
- Walsh, D. M., & Selkoe, D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. *Neuron*, *44*(1), 181–93. <https://doi.org/10.1016/j.neuron.2004.09.010>
- Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature*, *416*(6880), 535–39. <https://doi.org/10.1038/416535a>
- Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B., & Selkoe, D. J. (2000). The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. *Biochemistry*, *39*(35), 10831–839. <https://doi.org/10.1021/bi001048s>
- Wang, H.-W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., & Trommer, B. L. (2002). Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. *Brain Research*,

- 924(2), 133–40. [https://doi.org/10.1016/s0006-8993\(01\)03058-x](https://doi.org/10.1016/s0006-8993(01)03058-x)
- Wang, X., Wang, W., Li, L., Perry, G., Lee, H., & Zhu, X. (2014). Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. *Biochimica Et Biophysica Acta*, 1842(8), 1240–47. <https://doi.org/10.1016/j.bbadis.2013.10.015>
- Wasik, U., Schneider, G., Mietelska-Porowska, A., Mazurkiewicz, M., Fabczak, H., Weis, S., Zabke, C., Harrington, C. R., Filipek, A., & Niewiadomska, G. (2013). Calyculin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: Neuronal localization and possible function. *Neurobiology of Aging*, 34(5), 1380–1388. <https://doi.org/10.1016/j.neurobiolaging.2012.11.007>
- Wasmer, C., Lange, A., Van Melckebeke, H., Siemer, A. B., Riek, R., & Meier, B. H. (2008). Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. *Science (New York, N.Y.)*, 319(5869), 1523–26. <https://doi.org/10.1126/science.1151839>
- Weintraub, S., Wicklund, A. H., Salmon, D. P. The neuropsychological profile of Alzheimer disease. *Cold Spring Harb Perspect Med.* (2012) Apr;2(4):a006171. doi: 10.1101/cshperspect.a006171. PMID: 22474609; PMCID: PMC3312395
- Westermarck, P. (2005). Aspects on human amyloid forms and their fibril polypeptides. *The FEBS Journal*, 272(23), 5942–49. <https://doi.org/10.1111/j.1742-4658.2005.05024.x>
- Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012). CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. *PLoS One*, 7(1), e30525. <https://doi.org/10.1371/journal.pone.0030525>
- Whitehouse, P. J., Orgogozo, J. M., Becker, R. E., Gauthier, S., Pontecorvo, M., Erzigkeit, H., Rogers, S., Mohs, R. C., Bodick, N., Bruno, G., & Dal-Bianco, P. (1997). Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Disease and Associated Disorders*, 11 Suppl 3, 56–60.
- Wiatrak, B., Piasny, J., Kuźniarski, A., & Gąsiorowski, K. (2021). Interactions of Amyloid-β with Membrane Proteins. *International Journal of Molecular Sciences*, 22(11), 6075. <https://doi.org/10.3390/ijms22116075>
- Wiedrick, J. T., Phillips, J. I., Lusardi, T. A., McFarland, T. J., Lind, B., Sandau, U. S., Harrington, C. A., Lapidus, J. A., Galasko, D. R., Quinn, J. F., & Saugstad, J. A. (2019). Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. *Journal of Alzheimer's Disease: JAD*, 67(3), 875–91. <https://doi.org/10.3233/JAD-180539>
- Wilkins, H. M., & Swerdlow, R. H. (2017). Amyloid precursor protein processing and bioenergetics. *Brain Research Bulletin*, 133, 71–79. <https://doi.org/10.1016/j.brainresbull.2016.08.009>
- Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., Fratiglioni, L., Frisoni, G. B., Gauthier, S., Georges, J., Graff, C., Iqbal, K., Jessen, F.,

- Johansson, G., Jönsson, L., ... Zetterberg, H. (2016). Defeating Alzheimer's disease and other dementias: A priority for European science and society. *The Lancet. Neurology*, 15(5), 455–532. [https://doi.org/10.1016/S1474-4422\(16\)00062-4](https://doi.org/10.1016/S1474-4422(16)00062-4)
- Wojdała, A. L., Bellomo, G., Toja, A., Gaetani, L., Parnetti, L., & Chiasserini, D. (2024). CSF and plasma A $\beta$ 42/40 across Alzheimer's disease continuum: Comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions. *Clinical Chemistry and Laboratory Medicine*, 62(2), 332–40. <https://doi.org/10.1515/cclm-2023-0659>
- World Health Organization. Geneva, Switzerland: World Health Organization; (2021). Fact sheets of dementia [Internet] [cited 2022 Apr 13].
- Yamamoto, N., Fukata, Y., Fukata, M., & Yanagisawa, K. (2007). GM1-ganglioside- induced A $\beta$  assembly on synaptic membranes of cultured neurons. *Biochimica Et Biophysica Acta*, 1768(5), 1128–37. <https://doi.org/10.1016/j.bbamem.2007.01.009>
- Yamazaki, T., Koo, E. H., & Selkoe, D. J. (1997). Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 17(3), 1004–10. <https://doi.org/10.1523/JNEUROSCI.17-03-01004.1997>
- Yanagisawa, K. (2007). Role of gangliosides in Alzheimer's disease. *Biochimica Et Biophysica Acta*, 1768(8), 1943–51. <https://doi.org/10.1016/j.bbamem.2007.01.018>
- Yang, T., O'Malley, T. T., Kanmert, D., Jercic, J., Zieske, L. R., Zetterberg, H., Hyman, B. T., Walsh, D. M., & Selkoe, D. J. (2015). A highly sensitive novel immunoassay specifically detects low levels of soluble A $\beta$  oligomers in human cerebrospinal fluid. *Alzheimer's Research & Therapy*, 7(1), 14. <https://doi.org/10.1186/s13195-015-0100-y>
- Yerbury, J. J., & Wilson, M. R. (2010). Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on A $\beta$ (1–42) toxicity and uptake. *Cell Stress & Chaperones*, 15(1), 115–21. <https://doi.org/10.1007/s12192-009-0122-0>
- Yoshihara, T., Takiguchi, S., Kyuno, A., Tanaka, K., Kuba, S., Hashiguchi, S., Ito, Y., Hashimoto, T., Iwatsubo, T., Tsuyama, S., Nakashima, T., & Sugimura, K. (2008). Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro. *Journal of Biochemistry*, 143(4), 475–86. <https://doi.org/10.1093/jb/mvm239>
- Young-Pearse, T. L., Chen, A. C., Chang, R., Marquez, C., & Selkoe, D. J. (2008). Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. *Neural Development*, 3, 15. <https://doi.org/10.1186/1749-8104-3-15>
- Younkin, S. G. (1995). Evidence that A beta 42 is the real culprit in Alzheimer's disease. *Annals of Neurology*, 37(3), 287–88. <https://doi.org/10.1002/ana.410370303>

- Yu, Y. J., & Watts, R. J. (2013). Developing therapeutic antibodies for neurodegenerative disease. *Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics*, *10*(3), 459–72. <https://doi.org/10.1007/s13311-013-0187-4>
- Yuan, S., Zhou, G., & Xu, G. (2024). Translation machinery: The basis of translational control. *Journal of Genetics and Genomics = Yi Chuan Xue Bao*, *51*(4), 367–78. <https://doi.org/10.1016/j.jgg.2023.07.009>
- Yusakul, G., Sakamoto, S., Pongkitwitoon, B., Tanaka, H., & Morimoto, S. (2016). Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity. *Bioscience, Biotechnology and Biochemistry*, *80*(7), 1306–12. <https://doi.org/10.1080/09168451.2016.1156482>
- Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V., & Sierks, M. R. (2008). Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta- induced toxicity against human neuroblastoma cells. *Journal of Molecular Biology*, *384*(4), 917–28. <https://doi.org/10.1016/j.jmb.2008.09.068>
- Zampagni, M., Cascella, R., Casamenti, F., Grossi, C., Evangelisti, E., Wright, D., Becatti, M., Liguri, G., Mannini, B., Campioni, S., Chiti, F., & Cecchi, C. (2011). A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. *Journal of Cellular and Molecular Medicine*, *15*(10), 2106–16. <https://doi.org/10.1111/j.1582-4934.2010.01239.x>
- Zandomenighi, G., Krebs, M. R. H., McCammon, M. G., & Fändrich, M. (2004). FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils. *Protein Science: A Publication of the Protein Society*, *13*(12), 3314–21. <https://doi.org/10.1110/ps.041024904>
- Zetterberg, H., & Bendlin, B. B. (2021). Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies. *Molecular Psychiatry*, *26*(1), 296–308. <https://doi.org/10.1038/s41380-020-0721-9>
- Zetterberg, H., Alawode, D. O. T., Keshavan, A., O’Connor, A., Weston, P. S. J., Paterson, R. W., Heslegrave, A., Fox, N. C. Fox, Lunn, M. P., Schott, J. M. (2020). *Blood Tests for Alzheimer Disease*. Practical Neurology; Bryn Mawr Communications. Retrieved 8 January 2025, from <https://practicalneurology.com/articles/2020-nov-dec/blood-tests-for-alzheimer-disease>
- Zha, J., Liu, X.-M., Zhu, J., Liu, S.-Y., Lu, S., Xu, P.-X., Yu, X.-L., & Liu, R.-T. (2016). A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. *Scientific Reports*, *6*, 36631. <https://doi.org/10.1038/srep36631>
- Zhao, Y., & Zhao, B. (2013). Oxidative stress and the pathogenesis of Alzheimer’s disease. *Oxidative Medicine and Cellular Longevity*, *2013*, 316523. <https://doi.org/10.1155/2013/316523>
- Zheng, F., Pang, Y., Li, L., Pang, Y., Zhang, J., Wang, X., & Raes, G. (2022). Applications of nanobodies in brain diseases. *Frontiers in Immunology*, *13*, 978513. <https://doi.org/10.3389/fimmu.2022.978513>

Zhu, X., Perry, G., Smith, M. A., & Wang, X. (2013). Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*, 33 Suppl 1(0 1), S253-62. <https://doi.org/10.3233/JAD-2012-129005>.